Clinical Reports

Clinical Report Writing

Overview

Clinical report writing is the process of documenting medical information with precision, accuracy, and compliance with regulatory standards. This skill covers four major categories of clinical reports: case reports for journal publication, diagnostic reports for clinical practice, clinical trial reports for regulatory submission, and patient documentation for medical records. Apply this skill for healthcare documentation, research dissemination, and regulatory compliance.

Critical Principle: Clinical reports must be accurate, complete, objective, and compliant with applicable regulations (HIPAA, FDA, ICH-GCP). Patient privacy and data integrity are paramount. All clinical documentation must support evidence-based decision-making and meet professional standards.

When to Use This Skill

This skill should be used when:

• Writing clinical case reports for journal submission (CARE guidelines)
• Creating diagnostic reports (radiology, pathology, laboratory)
• Documenting clinical trial data and adverse events
• Preparing clinical study reports (CSR) for regulatory submission
• Writing patient progress notes, SOAP notes, and clinical summaries
• Drafting discharge summaries, H&P documents, or consultation notes
• Ensuring HIPAA compliance and proper de-identification
• Validating clinical documentation for completeness and accuracy
• Preparing serious adverse event (SAE) reports
• Creating data safety monitoring board (DSMB) reports

Visual Enhancement with Scientific Schematics

⚠️ MANDATORY: Every clinical report MUST include at least 1 AI-generated figure using the scientific-schematics skill.

This is not optional. Clinical reports benefit greatly from visual elements. Before finalizing any document: 1. Generate at minimum ONE schematic or diagram (e.g., patient timeline, diagnostic algorithm, or treatment workflow) 2. For case reports: include clinical progression timeline 3. For trial reports: include CONSORT flow diagram

How to generate figures:

• Use the scientific-schematics skill to generate AI-powered publication-quality diagrams
• Simply describe your desired diagram in natural language
• Nano Banana Pro will automatically generate, review, and refine the schematic

How to generate schematics:

python scripts/generate_schematic.py "your diagram description" -o figures/output.png

The AI will automatically:

• Create publication-quality images with proper formatting
• Review and refine through multiple iterations
• Ensure accessibility (colorblind-friendly, high contrast)
• Save outputs in the figures/ directory

When to add schematics:

• Patient case timelines and clinical progression diagrams
• Diagnostic algorithm flowcharts
• Treatment protocol workflows
• Anatomical diagrams for case reports
• Clinical trial participant flow diagrams (CONSORT)
• Adverse event classification trees
• Any complex concept that benefits from visualization

For detailed guidance on creating schematics, refer to the scientific-schematics skill documentation.

---

Core Capabilities

1. Clinical Case Reports for Journal Publication

Clinical case reports describe unusual clinical presentations, novel diagnoses, or rare complications. They contribute to medical knowledge and are published in peer-reviewed journals.

CARE Guidelines Compliance

The CARE (CAse REport) guidelines provide a standardized framework for case report writing. All case reports should follow this checklist:

Title

• Include the words "case report" or "case study"
• Indicate the area of focus
• Example: "Unusual Presentation of Acute Myocardial Infarction in a Young Patient: A Case Report"

Keywords

• 2-5 keywords for indexing and searchability
• Use MeSH (Medical Subject Headings) terms when possible

Abstract (structured or unstructured, 150-250 words)

• Introduction: What is unique or novel about the case?
• Patient concerns: Primary symptoms and key medical history
• Diagnoses: Primary and secondary diagnoses
• Interventions: Key treatments and procedures
• Outcomes: Clinical outcome and follow-up
• Conclusions: Main takeaway or clinical lesson

Introduction

• Brief background on the medical condition
• Why this case is novel or important
• Literature review of similar cases (brief)
• What makes this case worth reporting

Patient Information

• Demographics (age, sex, race/ethnicity if relevant)
• Medical history, family history, social history
• Relevant comorbidities
• De-identification: Remove or alter 18 HIPAA identifiers
• Patient consent: Document informed consent for publication

Clinical Findings

• Chief complaint and presenting symptoms
• Physical examination findings
• Timeline of symptoms (consider timeline figure or table)
• Relevant clinical observations

Timeline

• Chronological summary of key events
• Dates of symptoms, diagnosis, interventions, outcomes
• Can be presented as a table or figure
• Example format:
• Day 0: Initial presentation with symptoms X, Y, Z
• Day 2: Diagnostic test A performed, revealed finding B
• Day 5: Treatment initiated with drug C
• Day 14: Clinical improvement noted
• Month 3: Follow-up examination shows complete resolution

Diagnostic Assessment

• Diagnostic tests performed (labs, imaging, procedures)
• Results and interpretation
• Differential diagnosis considered
• Rationale for final diagnosis
• Challenges in diagnosis

Therapeutic Interventions

• Medications (names, dosages, routes, duration)
• Procedures or surgeries performed
• Non-pharmacological interventions
• Reasoning for treatment choices
• Alternative treatments considered

Follow-up and Outcomes

• Clinical outcome (resolution, improvement, unchanged, worsened)
• Follow-up duration and frequency
• Long-term outcomes if available
• Patient-reported outcomes
• Adherence to treatment

Discussion

• Strengths and novelty of the case
• How this case compares to existing literature
• Limitations of the case report
• Potential mechanisms or explanations
• Clinical implications and lessons learned
• Unanswered questions or areas for future research

Patient Perspective (optional but encouraged)

• Patient's experience and viewpoint
• Impact on quality of life
• Patient-reported outcomes
• Quote from patient if appropriate

Informed Consent

• Statement documenting patient consent for publication
• If patient deceased or unable to consent, describe proxy consent
• For pediatric cases, parental/guardian consent
• Example: "Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal."

For detailed CARE guidelines, refer to references/case_report_guidelines.md.

Journal-Specific Requirements

Different journals have specific formatting requirements:

• Word count limits (typically 1500-3000 words)
• Number of figures/tables allowed
• Reference style (AMA, Vancouver, APA)
• Structured vs. unstructured abstract
• Supplementary materials policies

Check journal instructions for authors before submission.

De-identification and Privacy

18 HIPAA Identifiers to Remove or Alter: 1. Names 2. Geographic subdivisions smaller than state 3. Dates (except year) 4. Telephone numbers 5. Fax numbers 6. Email addresses 7. Social Security numbers 8. Medical record numbers 9. Health plan beneficiary numbers 10. Account numbers 11. Certificate/license numbers 12. Vehicle identifiers and serial numbers 13. Device identifiers and serial numbers 14. Web URLs 15. IP addresses 16. Biometric identifiers 17. Full-face photographs 18. Any other unique identifying characteristic

Best Practices:

• Use "the patient" instead of names
• Report age ranges (e.g., "a woman in her 60s") or exact age if relevant
• Use approximate dates or time intervals (e.g., "3 months prior")
• Remove institution names unless necessary
• Blur or crop identifying features in images
• Obtain explicit consent for any potentially identifying information

2. Clinical Diagnostic Reports

Diagnostic reports communicate findings from imaging studies, pathological examinations, and laboratory tests. They must be clear, accurate, and actionable.

Radiology Reports

Radiology reports follow a standardized structure to ensure clarity and completeness.

Standard Structure:

1. Patient Demographics

• Patient name (or ID in research contexts)
• Date of birth or age
• Medical record number
• Examination date and time

2. Clinical Indication

• Reason for examination
• Relevant clinical history
• Specific clinical question to be answered
• Example: "Rule out pulmonary embolism in patient with acute dyspnea"

3. Technique

• Imaging modality (X-ray, CT, MRI, ultrasound, PET, etc.)
• Anatomical region examined
• Contrast administration (type, route, volume)
• Protocol or sequence used
• Technical quality and limitations
• Example: "Contrast-enhanced CT of the chest, abdomen, and pelvis was performed using 100 mL of intravenous iodinated contrast. Oral contrast was not administered."

4. Comparison

• Prior imaging studies available for comparison
• Dates of prior studies
• Stability or change from prior imaging
• Example: "Comparison: CT chest from [date]"

5. Findings

• Systematic description of imaging findings
• Organ-by-organ or region-by-region approach
• Positive findings first, then pertinent negatives
• Measurements of lesions or abnormalities
• Use of standardized terminology (ACR lexicon, RadLex)
• Example:
• Lungs: Bilateral ground-glass opacities, predominant in the lower lobes. No consolidation or pleural effusion.
• Mediastinum: No lymphadenopathy. Heart size normal.
• Abdomen: Liver, spleen, pancreas unremarkable. No free fluid.

6. Impression/Conclusion

• Concise summary of key findings
• Answers to the clinical question
• Differential diagnosis if applicable
• Recommendations for follow-up or additional studies
• Level of suspicion or diagnostic certainty
• Example:
• "1. Bilateral ground-glass opacities consistent with viral pneumonia or atypical infection. COVID-19 cannot be excluded. Clinical correlation recommended.
• 2. No evidence of pulmonary embolism.
• 3. Recommend follow-up imaging in 4-6 weeks to assess resolution."

Structured Reporting:

Many radiology departments use structured reporting templates for common examinations:

• Lung nodule reporting (Lung-RADS)
• Breast imaging (BI-RADS)
• Liver imaging (LI-RADS)
• Prostate imaging (PI-RADS)
• CT colonography (C-RADS)

Structured reports improve consistency, reduce ambiguity, and facilitate data extraction.

For radiology reporting standards, see references/diagnostic_reports_standards.md.

Pathology Reports

Pathology reports document microscopic findings from tissue specimens and provide diagnostic conclusions.

Surgical Pathology Report Structure:

1. Patient Information

• Patient name and identifiers
• Date of birth, age, sex
• Ordering physician
• Medical record number
• Specimen received date

2. Specimen Information

• Specimen type (biopsy, excision, resection)
• Anatomical site
• Laterality if applicable
• Number of specimens/blocks/slides
• Example: "Skin, left forearm, excisional biopsy"

3. Clinical History

• Relevant clinical information
• Indication for biopsy
• Prior diagnoses
• Example: "History of melanoma. New pigmented lesion, rule out recurrence."

4. Gross Description

• Macroscopic appearance of specimen
• Size, weight, color, consistency
• Orientation markers if present
• Sectioning and sampling approach
• Example: "The specimen consists of an ellipse of skin measuring 2.5 x 1.0 x 0.5 cm. A pigmented lesion measuring 0.6 cm in diameter is present on the surface. The specimen is serially sectioned and entirely submitted in cassettes A1-A3."

5. Microscopic Description

• Histological findings
• Cellular characteristics
• Architectural patterns
• Presence of malignancy
• Margins if applicable
• Special stains or immunohistochemistry results

6. Diagnosis

• Primary diagnosis
• Grade and stage if applicable (cancer)
• Margin status
• Lymph node status if applicable
• Synoptic reporting for cancers (CAP protocols)
• Example:
• "MALIGNANT MELANOMA, SUPERFICIAL SPREADING TYPE
• Breslow thickness: 1.2 mm
• Clark level: IV
• Mitotic rate: 3/mm²
• Ulceration: Absent
• Margins: Negative (closest margin 0.4 cm)
• Lymphovascular invasion: Not identified"

7. Comment (if needed)

• Additional context or interpretation
• Differential diagnosis
• Recommendations for additional studies
• Clinical correlation suggestions

Synoptic Reporting:

The College of American Pathologists (CAP) provides synoptic reporting templates for cancer specimens. These checklists ensure all relevant diagnostic elements are documented.

Key elements for cancer reporting:

• Tumor site
• Tumor size
• Histologic type
• Histologic grade
• Extent of invasion
• Lymph-vascular invasion
• Perineural invasion
• Margins
• Lymph nodes (number examined, number positive)
• Pathologic stage (TNM classification)
• Ancillary studies (molecular markers, biomarkers)

Laboratory Reports

Laboratory reports communicate test results for clinical specimens (blood, urine, tissue, etc.).

Standard Components:

1. Patient and Specimen Information

• Patient identifiers
• Specimen type (blood, serum, urine, CSF, etc.)
• Collection date and time
• Received date and time
• Ordering provider

2. Test Name and Method

• Full test name
• Methodology (immunoassay, spectrophotometry, PCR, etc.)
• Laboratory accession number

3. Results

• Quantitative or qualitative result
• Units of measurement
• Reference range (normal values)
• Flags for abnormal values (H = high, L = low)
• Critical values highlighted
• Example:
• Hemoglobin: 8.5 g/dL (L) [Reference: 12.0-16.0 g/dL]
• White Blood Cell Count: 15.2 x10³/μL (H) [Reference: 4.5-11.0 x10³/μL]

4. Interpretation (when applicable)

• Clinical significance of results
• Suggested follow-up or additional testing
• Correlation with diagnosis
• Drug levels and therapeutic ranges

5. Quality Control Information

• Specimen adequacy
• Specimen quality issues (hemolyzed, lipemic, clotted)
• Delays in processing
• Technical limitations

Critical Value Reporting:

• Life-threatening results require immediate notification
• Examples: glucose <40 or >500 mg/dL, potassium <2.5 or >6.5 mEq/L
• Document notification time and recipient

For laboratory standards and terminology, see references/diagnostic_reports_standards.md.

3. Clinical Trial Reports

Clinical trial reports document the conduct, results, and safety of clinical research studies. These reports are essential for regulatory submissions and scientific publication.

Serious Adverse Event (SAE) Reports

SAE reports document unexpected serious adverse reactions during clinical trials. Regulatory requirements mandate timely reporting to IRBs, sponsors, and regulatory agencies.

Definition of Serious Adverse Event: An adverse event is serious if it:

• Results in death
• Is life-threatening
• Requires inpatient hospitalization or prolongation of existing hospitalization
• Results in persistent or significant disability/incapacity
• Is a congenital anomaly/birth defect
• Requires intervention to prevent permanent impairment or damage

SAE Report Components:

1. Study Information

• Protocol number and title
• Study phase
• Sponsor name
• Principal investigator
• IND/IDE number (if applicable)
• Clinical trial registry number (NCT number)

2. Patient Information (De-identified)

• Subject ID or randomization number
• Age, sex, race/ethnicity
• Study arm or treatment group
• Date of informed consent
• Date of first study intervention

3. Event Information

• Event description (narrative)
• Date of onset
• Date of resolution (or ongoing)
• Severity (mild, moderate, severe)
• Seriousness criteria met
• Outcome (recovered, recovering, not recovered, fatal, unknown)

4. Causality Assessment

• Relationship to study intervention (unrelated, unlikely, possible, probable, definite)
• Relationship to study procedures
• Relationship to underlying disease
• Rationale for causality determination

5. Action Taken

• Modification of study intervention (dose reduction, temporary hold, permanent discontinuation)
• Concomitant medications or treatments administered
• Hospitalization details
• Outcome and follow-up plan

6. Expectedness

• Expected per protocol or investigator's brochure
• Unexpected event requiring expedited reporting
• Comparison to known safety profile

7. Narrative

• Detailed description of the event
• Timeline of events
• Clinical course and management
• Laboratory and diagnostic test results
• Final diagnosis or conclusion

8. Reporter Information

• Name and contact of reporter
• Report date
• Signature

Regulatory Timelines:

• Fatal or life-threatening unexpected SAEs: 7 days for preliminary report, 15 days for complete report
• Other serious unexpected events: 15 days
• IRB notification: per institutional policy, typically within 5-10 days

For detailed SAE reporting guidance, see references/clinical_trial_reporting.md.

Clinical Study Reports (CSR)

Clinical study reports are comprehensive documents summarizing the design, conduct, and results of clinical trials. They are submitted to regulatory agencies as part of drug approval applications.

ICH-E3 Structure:

The ICH E3 guideline defines the structure and content of clinical study reports.

Main Sections:

1. Title Page

• Study title and protocol number
• Sponsor and investigator information
• Report date and version

2. Synopsis (5-15 pages)

• Brief summary of entire study
• Objectives, methods, results, conclusions
• Key efficacy and safety findings
• Can stand alone

3. Table of Contents

4. List of Abbreviations and Definitions

5. Ethics (Section 2)

• IRB/IEC approvals
• Informed consent process
• GCP compliance statement

6. Investigators and Study Administrative Structure (Section 3)

• List of investigators and sites
• Study organization
• Monitoring and quality assurance

7. Introduction (Section 4)

• Background and rationale
• Study objectives and purpose

8. Study Objectives and Plan (Section 5)

• Overall design and plan
• Objectives (primary and secondary)
• Endpoints (efficacy and safety)
• Sample size determination

9. Study Patients (Section 6)

• Inclusion and exclusion criteria
• Patient disposition
• Protocol deviations
• Demographic and baseline characteristics

10. Efficacy Evaluation (Section 7)

• Data sets analyzed (ITT, PP, safety)
• Demographic and other baseline characteristics
• Efficacy results for primary and secondary endpoints
• Subgroup analyses
• Dropouts and missing data

11. Safety Evaluation (Section 8)

• Extent of exposure
• Adverse events (summary tables)
• Serious adverse events (narratives)
• Laboratory values
• Vital signs and physical findings
• Deaths and other serious events

12. Discussion and Overall Conclusions (Section 9)

• Interpretation of results
• Benefit-risk assessment
• Clinical implications

13. Tables, Figures, and Graphs (Section 10)

14. Reference List (Section 11)

15. Appendices (Section 12)

• Study protocol and amendments
• Sample case report forms
• List of investigators and ethics committees
• Patient information and consent forms
• Investigator's brochure references
• Publications based on the study

Key Principles:

• Objectivity and transparency
• Comprehensive data presentation
• Adherence to statistical analysis plan
• Clear presentation of safety data
• Integration of appendices

For ICH-E3 templates and detailed guidance, see references/clinical_trial_reporting.md and assets/clinical_trial_csr_template.md.

Protocol Deviations

Protocol deviations are departures from the approved study protocol. They must be documented, assessed, and reported.

Categories:

• Minor deviation: Does not significantly impact patient safety or data integrity
• Major deviation: May impact patient safety, data integrity, or study conduct
• Violation: Serious deviation requiring immediate action and reporting

Documentation Requirements:

• Description of deviation
• Date of occurrence
• Subject ID affected
• Impact on safety and data
• Corrective and preventive actions (CAPA)
• Root cause analysis
• Preventive measures implemented

4. Patient Clinical Documentation

Patient documentation records clinical encounters, progress, and care plans. Accurate documentation supports continuity of care, billing, and legal protection.

SOAP Notes

SOAP notes are the most common format for progress notes in clinical practice.

Structure:

S - Subjective

• Patient's reported symptoms and concerns
• History of present illness (HPI)
• Review of systems (ROS) relevant to visit
• Patient's own words (use quotes when helpful)
• Example: "Patient reports worsening shortness of breath over the past 3 days, particularly with exertion. Denies chest pain, fever, or cough."

O - Objective

• Measurable clinical findings
• Vital signs (temperature, blood pressure, heart rate, respiratory rate, oxygen saturation)
• Physical examination findings (organized by system)
• Laboratory and imaging results
• Example:
• Vitals: T 98.6°F, BP 142/88, HR 92, RR 22, SpO2 91% on room air
• General: Mild respiratory distress
• Cardiovascular: Regular rhythm, no murmurs
• Pulmonary: Bilateral crackles at bases
• Extremities: 2+ pitting edema bilaterally

A - Assessment

• Clinical impression or diagnosis
• Differential diagnosis
• Severity and stability
• Progress toward treatment goals
• Example:
• "1. Acute decompensated heart failure, NYHA Class III
• 2. Hypertension, poorly controlled
• 3. Chronic kidney disease, stage 3"

P - Plan

• Diagnostic plan (further testing)
• Therapeutic plan (medications, procedures)
• Patient education and counseling
• Follow-up arrangements
• Example:
• "Diagnostics: BNP, chest X-ray, echocardiogram
• Therapeutics: Increase furosemide to 40 mg PO BID, continue lisinopril 10 mg daily, strict fluid restriction to 1.5 L/day
• Education: Signs of worsening heart failure, daily weights
• Follow-up: Cardiology appointment in 1 week, call if weight gain >2 lbs in 1 day"

Documentation Tips:

• Be concise but complete
• Use standard medical abbreviations
• Document time of encounter
• Sign and date all notes
• Avoid speculation or judgment
• Document medical necessity for billing
• Include patient's response to treatment

For SOAP note templates and examples, see assets/soap_note_template.md.

History and Physical (H&P)

The H&P is a comprehensive assessment performed at admission or initial encounter.

Components:

1. Chief Complaint (CC)

• Brief statement of why patient is seeking care
• Use patient's own words
• Example: "Chest pain for 2 hours"

2. History of Present Illness (HPI)

• Detailed chronological narrative of current problem
• Use OPQRST mnemonic for pain:
• Onset: When did it start?
• Provocation/Palliation: What makes it better or worse?
• Quality: What does it feel like?
• Region/Radiation: Where is it? Does it spread?
• Severity: How bad is it (0-10 scale)?
• Timing: Constant or intermittent? Duration?
• Associated symptoms
• Prior evaluations or treatments

3. Past Medical History (PMH)

• Chronic medical conditions
• Previous hospitalizations
• Surgeries and procedures
• Example: "Hypertension (diagnosed 2015), type 2 diabetes mellitus (diagnosed 2018), prior appendectomy (2010)"

4. Medications

• Current medications with doses and frequencies
• Over-the-counter medications
• Herbal supplements
• Allergies and reactions

5. Allergies

• Drug allergies with type of reaction
• Food allergies
• Environmental allergies
• Example: "Penicillin (rash), shellfish (anaphylaxis)"

6. Family History (FH)

• Medical conditions in first-degree relatives
• Age and cause of death of parents
• Hereditary conditions
• Example: "Father with coronary artery disease (MI at age 55), mother with breast cancer (diagnosed age 62)"

7. Social History (SH)

• Tobacco use (pack-years)
• Alcohol use (drinks per week)
• Illicit drug use
• Occupation
• Living situation
• Sexual history if relevant
• Example: "Former smoker, quit 5 years ago (20 pack-year history). Occasional alcohol (2-3 drinks/week). Works as accountant. Lives with spouse."

8. Review of Systems (ROS)

• Systematic review of symptoms by organ system
• Typically 10-14 systems
• Pertinent positives and negatives
• Systems: Constitutional, Eyes, ENT, Cardiovascular, Respiratory, GI, GU, Musculoskeletal, Skin, Neurological, Psychiatric, Endocrine, Hematologic/Lymphatic, Allergic/Immunologic

9. Physical Examination

• Vital signs
• General appearance
• Systematic examination by organ system
• HEENT, Neck, Cardiovascular, Pulmonary, Abdomen, Extremities, Neurological, Skin
• Use standard terminology and abbreviations

10. Assessment and Plan

• Problem list with assessment and plan for each
• Numbered list format
• Diagnostic and therapeutic plans
• Disposition (admit, discharge, transfer)

For H&P templates, see assets/history_physical_template.md.

Discharge Summaries

Discharge summaries document the hospital stay and communicate care plan to outpatient providers.

Required Elements:

1. Patient Identification

• Name, date of birth, medical record number
• Admission and discharge dates
• Attending physician
• Admitting and discharge diagnoses

2. Reason for Hospitalization

• Brief description of presenting problem
• Chief complaint

3. Hospital Course

• Chronological narrative of key events
• Significant findings and procedures
• Response to treatment
• Complications
• Consultations obtained
• Organized by problem or chronologically

4. Discharge Diagnoses

• Primary diagnosis
• Secondary diagnoses
• Complications
• Comorbidities

5. Procedures Performed

• Surgeries
• Invasive procedures
• Diagnostic procedures

6. Discharge Medications

• Complete medication list with instructions
• Changes from admission medications
• New medications with indications

7. Discharge Condition

• Stable, improved, unchanged, expired
• Functional status
• Mental status

8. Discharge Disposition

• Home, skilled nursing facility, rehabilitation, hospice
• With or without services

9. Follow-up Plans

• Appointments scheduled
• Recommended follow-up timing
• Pending tests or studies
• Referrals

10. Patient Instructions

• Activity restrictions
• Dietary restrictions
• Wound care
• Warning signs to seek care
• Medication instructions

Best Practices:

• Complete within 24-48 hours of discharge
• Use clear language for outpatient providers
• Highlight important pending results
• Document code status discussions
• Include patient education provided

For discharge summary templates, see assets/discharge_summary_template.md.

Regulatory Compliance and Privacy

HIPAA Compliance

The Health Insurance Portability and Accountability Act (HIPAA) mandates protection of patient health information.

Key Requirements:

• Minimum necessary disclosure
• Patient authorization for use beyond treatment/payment/operations
• Secure storage and transmission
• Audit trails for electronic records
• Breach notification procedures

De-identification Methods: 1. Safe Harbor Method: Remove 18 identifiers 2. Expert Determination: Statistical method confirming low re-identification risk

Business Associate Agreements: Required when PHI is shared with third parties for services

For detailed HIPAA guidance, see references/regulatory_compliance.md.

FDA Regulations

Clinical trial documentation must comply with FDA regulations:

• 21 CFR Part 11 (Electronic Records and Signatures)
• 21 CFR Part 50 (Informed Consent)
• 21 CFR Part 56 (IRB Standards)
• 21 CFR Part 312 (IND Regulations)

ICH-GCP Guidelines

Good Clinical Practice (GCP) guidelines ensure quality and ethical standards in clinical trials:

• Protocol adherence
• Informed consent documentation
• Source document requirements
• Audit trails and data integrity
• Investigator responsibilities

For ICH-GCP compliance, see references/regulatory_compliance.md.

Medical Terminology and Standards

Standardized Nomenclature

SNOMED CT (Systematized Nomenclature of Medicine - Clinical Terms)

• Comprehensive clinical terminology
• Used for electronic health records
• Enables semantic interoperability

LOINC (Logical Observation Identifiers Names and Codes)

• Standard for laboratory and clinical observations
• Facilitates data exchange and reporting

ICD-10-CM (International Classification of Diseases, 10th Revision, Clinical Modification)

• Diagnosis coding for billing and epidemiology
• Required for reimbursement

CPT (Current Procedural Terminology)

• Procedure coding for billing
• Maintained by AMA

Abbreviation Standards

Acceptable Abbreviations: Use standard abbreviations to improve efficiency while maintaining clarity.

Do Not Use List (Joint Commission):

• U (unit) - write "unit"
• IU (international unit) - write "international unit"
• QD, QOD (daily, every other day) - write "daily" or "every other day"
• Trailing zero (X.0 mg) - never use after decimal
• Lack of leading zero (.X mg) - always use before decimal (0.X mg)
• MS, MSO4, MgSO4 - write "morphine sulfate" or "magnesium sulfate"

For comprehensive terminology standards, see references/medical_terminology.md.

Quality Assurance and Validation

Documentation Quality Principles

Completeness:

• All required elements present
• No missing data fields
• Comprehensive patient information

Accuracy:

• Factually correct information
• Verified data sources
• Appropriate clinical reasoning

Timeliness:

• Documented contemporaneously or shortly after encounter
• Time-sensitive reports prioritized
• Regulatory deadlines met

Clarity:

• Clear and unambiguous language
• Organized logical structure
• Appropriate use of medical terminology

Compliance:

• Regulatory requirements met
• Privacy protections in place
• Institutional policies followed

Validation Checklists

For each report type, use validation checklists to ensure quality:

• Case report CARE checklist
• Diagnostic report completeness
• SAE report regulatory compliance
• Clinical documentation billing requirements

Validation scripts are available in the scripts/ directory.

Data Presentation in Clinical Reports

Tables and Figures

Tables for Clinical Data:

• Demographic and baseline characteristics
• Adverse events summary
• Laboratory values over time
• Efficacy outcomes

Table Design Principles:

• Clear column headers with units
• Footnotes for abbreviations and statistical notes
• Consistent formatting
• Appropriate precision (significant figures)

Figures for Clinical Data:

• Kaplan-Meier survival curves
• Forest plots for subgroup analyses
• Patient flow diagrams (CONSORT)
• Timeline figures for case reports
• Before-and-after images

Image Guidelines:

• High resolution (300 dpi minimum)
• Appropriate scale bars
• Annotations for key features
• De-identified (no patient identifiers visible)
• Informed consent for recognizable images

For data presentation standards, see references/data_presentation.md.

Integration with Other Skills

This clinical reports skill integrates with:

• Scientific Writing: For clear, professional medical writing
• Peer Review: For quality assessment of case reports
• Citation Management: For literature references in case reports
• Research Grants: For clinical trial protocol development
• Literature Review: For background sections in case reports

Workflow for Clinical Report Writing

Case Report Workflow

Phase 1: Case Identification and Consent (Week 1)

• Identify novel or educational case
• Obtain patient informed consent
• De-identify patient information
• Collect clinical data and images

Phase 2: Literature Review (Week 1-2)

• Search for similar cases
• Review relevant pathophysiology
• Identify knowledge gaps
• Determine novelty and significance

Phase 3: Drafting (Week 2-3)

• Write structured outline following CARE guidelines
• Draft all sections (abstract through discussion)
• Create timeline and figures
• Format references

Phase 4: Internal Review (Week 3-4)

• Co-author review
• Attending physician review
• Institutional review if required
• Patient review of de-identified draft

Phase 5: Journal Selection and Submission (Week 4-5)

• Select appropriate journal
• Format per journal guidelines
• Prepare cover letter
• Submit manuscript

Phase 6: Revision (Variable)

• Respond to peer reviewer comments
• Revise manuscript
• Resubmit

Diagnostic Report Workflow

Real-time Workflow:

• Review clinical indication and prior studies
• Interpret imaging, pathology, or laboratory findings
• Dictate or type report using structured format
• Peer review for complex cases
• Final sign-out and distribution
• Critical value notification if applicable

Turnaround Time Benchmarks:

• STAT reports: <1 hour
• Routine reports: 24-48 hours
• Complex cases: 2-5 days
• Pending additional studies: documented delay

Clinical Trial Report Workflow

SAE Report: 24 hours to 15 days

• Event identified by site
• Initial assessment and documentation
• Causality and expectedness determination
• Report completion and review
• Submission to sponsor, IRB, FDA (as required)
• Follow-up reporting until resolution

CSR: 6-12 months post-study completion

• Database lock and data cleaning
• Statistical analysis per SAP
• Drafting by medical writer
• Review by biostatistician and clinical team
• Quality control review
• Final approval and regulatory submission

Resources

This skill includes comprehensive reference files and templates:

Reference Files

• references/case_report_guidelines.md - CARE guidelines, journal requirements, writing tips
• references/diagnostic_reports_standards.md - ACR, CAP, laboratory reporting standards
• references/clinical_trial_reporting.md - ICH-E3, CONSORT, SAE reporting, CSR structure
• references/patient_documentation.md - SOAP notes, H&P, discharge summaries, coding
• references/regulatory_compliance.md - HIPAA, 21 CFR Part 11, ICH-GCP, FDA requirements
• references/medical_terminology.md - SNOMED, LOINC, ICD-10, abbreviations, nomenclature
• references/data_presentation.md - Tables, figures, safety data, CONSORT diagrams
• references/peer_review_standards.md - Review criteria for clinical manuscripts

Template Assets

• assets/case_report_template.md - Structured case report following CARE guidelines
• assets/radiology_report_template.md - Standard radiology report format
• assets/pathology_report_template.md - Surgical pathology report with synoptic elements
• assets/lab_report_template.md - Clinical laboratory report format
• assets/clinical_trial_sae_template.md - Serious adverse event report form
• assets/clinical_trial_csr_template.md - Clinical study report outline per ICH-E3
• assets/soap_note_template.md - SOAP progress note format
• assets/history_physical_template.md - Comprehensive H&P template
• assets/discharge_summary_template.md - Hospital discharge summary
• assets/consult_note_template.md - Consultation note format
• assets/quality_checklist.md - Quality assurance checklist for all report types
• assets/hipaa_compliance_checklist.md - Privacy and de-identification checklist

Automation Scripts

• scripts/validate_case_report.py - Check CARE guideline compliance and completeness
• scripts/validate_trial_report.py - Verify ICH-E3 structure and required elements
• scripts/check_deidentification.py - Scan for 18 HIPAA identifiers in text
• scripts/format_adverse_events.py - Generate AE summary tables from data
• scripts/generate_report_template.py - Interactive template selection and generation
• scripts/extract_clinical_data.py - Parse structured data from clinical reports
• scripts/compliance_checker.py - Verify regulatory compliance requirements
• scripts/terminology_validator.py - Validate medical terminology and coding

Load these resources as needed when working on specific clinical reports.

Common Pitfalls to Avoid

Case Reports

• Privacy violations: Inadequate de-identification or missing consent
• Lack of novelty: Reporting common or well-documented cases
• Insufficient detail: Missing key clinical information
• Poor literature review: Failure to contextualize within existing knowledge
• Overgeneralization: Drawing broad conclusions from single case

Diagnostic Reports

• Vague language: Using ambiguous terms like "unremarkable" without specifics
• Incomplete comparison: Not reviewing prior imaging
• Missing clinical correlation: Failing to answer clinical question
• Technical jargon: Overuse of terminology without explanation
• Delayed critical value notification: Not communicating urgent findings

Clinical Trial Reports

• Late reporting: Missing regulatory deadlines for SAE reporting
• Incomplete causality: Inadequate causality assessment
• Data inconsistencies: Discrepancies between data sources
• Protocol deviations: Unreported or inadequately documented deviations
• Selective reporting: Omitting negative or unfavorable results

Patient Documentation

• Illegibility: Poor handwriting in paper records
• Copy-forward errors: Propagating outdated information
• Insufficient detail: Vague or incomplete documentation affecting billing
• Lack of medical necessity: Not documenting indication for services
• Missing signatures: Unsigned or undated notes

Final Checklist

Before finalizing any clinical report, verify:

• [ ] All required sections complete
• [ ] Patient privacy protected (HIPAA compliance)
• [ ] Informed consent obtained (if applicable)
• [ ] Accurate and verified clinical data
• [ ] Appropriate medical terminology and coding
• [ ] Clear, professional language
• [ ] Proper formatting per guidelines
• [ ] References cited appropriately
• [ ] Figures and tables labeled correctly
• [ ] Spell-checked and proofread
• [ ] Regulatory requirements met
• [ ] Institutional policies followed
• [ ] Signatures and dates present
• [ ] Quality assurance review completed

---

Final Note: Clinical report writing requires attention to detail, medical accuracy, regulatory compliance, and clear communication. Whether documenting patient care, reporting research findings, or communicating diagnostic results, the quality of clinical reports directly impacts patient safety, healthcare delivery, and medical knowledge advancement. Always prioritize accuracy, privacy, and professionalism in all clinical documentation.

Clinical Case Report Template

Title

[Insert descriptive title that includes "Case Report" or "Case Study" and indicates the clinical focus]

Example: Unusual Presentation of Acute Appendicitis in an Elderly Patient: A Case Report

Author Information

[Author names, affiliations, ORCID IDs]

Corresponding Author: [Name] [Email] [Institution]

Keywords

[2-5 keywords, preferably MeSH terms]

Example: Appendicitis, Atypical presentation, Elderly, Diagnostic imaging

Abstract

Introduction

[What is unique about this case? Why is it worth reporting? 1-2 sentences]

Patient Concerns

[Primary symptoms and chief complaint]

Diagnosis

[Final diagnosis, how it was reached]

Interventions

[Key treatments provided]

Outcomes

[Clinical outcome and follow-up status]

Lessons

[Main takeaway messages for clinicians]

Word count: [150-250 words]

Introduction

[Background information - 2-4 paragraphs]

Paragraph 1: Background on the condition

• Epidemiology of the condition
• Typical clinical presentation
• Standard diagnostic approach
• Current treatment guidelines

Paragraph 2: Why this case is novel

• What makes this case unusual or important
• Gap in medical knowledge addressed
• Literature review showing rarity or uniqueness
• Clinical significance

Paragraph 3: Objectives

• Purpose of reporting this case
• Learning points to be highlighted

Patient Information

Demographics:

• Age: [e.g., "A 72-year-old" or "A woman in her 70s"]
• Sex: [Male/Female]
• Ethnicity: [if relevant to case]
• Occupation: [if relevant]

Medical History:

• Past medical history: [chronic conditions]
• Past surgical history: [prior surgeries]
• Family history: [relevant family history]
• Social history: [tobacco, alcohol, occupation, living situation]

Medications:

• Current medications: [list with doses]
• Allergies: [drug allergies and reactions]

Presenting Symptoms:

• Chief complaint: ["Patient's words" or clinical presentation]
• Duration of symptoms
• Severity and characteristics
• Associated symptoms
• Relevant review of systems

Clinical Findings

Physical Examination:

• Vital signs: [T, BP, HR, RR, SpO2]
• General appearance: [overall state]
• Systematic examination by organ system:
• HEENT: [findings]
• Cardiovascular: [findings]
• Respiratory: [findings]
• Abdomen: [findings]
• Neurological: [findings]
• Other relevant systems: [findings]

Pertinent Negatives: [Important negative findings]

Timeline

Note: Use relative days (Day 0, Day 1) or approximate dates (Month 1, Month 3) to protect patient privacy

Diagnostic Assessment

Initial Diagnostic Workup

Laboratory Tests:

Imaging Studies:

• [Modality] ([Date]): [Key findings]
• [Include images if applicable, with labels and arrows pointing to key findings]

Other Diagnostic Procedures:

• [Procedure name] ([Date]): [Findings]

Differential Diagnosis

Diagnoses Considered: 1. [Primary differential]

• Supporting evidence:
• Evidence against:

2. [Alternative diagnosis]

• Supporting evidence:
• Evidence against:

3. [Additional differentials as appropriate]

Diagnostic Challenges

[Describe any difficulties in reaching the diagnosis]

• Atypical presentation
• Misleading initial findings
• Diagnostic delays
• Complex decision-making

Final Diagnosis

Confirmed Diagnosis: [Final diagnosis with ICD-10 code if applicable]

Diagnostic Reasoning: [Explain how diagnosis was reached, key diagnostic features, confirmatory tests]

Therapeutic Intervention

Treatment Approach

Initial Management:

• [Immediate interventions]
• [Supportive care]
• [Monitoring]

Definitive Treatment: 1. Pharmacological Interventions:

• [Drug name]: [Dose, route, frequency, duration]
• Indication: [Why prescribed]
• Response: [Patient response to treatment]

2. Procedural/Surgical Interventions:

• [Procedure name] performed on [date/day]
• Indication: [Why performed]
• Technique: [Brief description]
• Findings: [Intraoperative or procedural findings]
• Complications: [Any complications or none]

3. Other Interventions:

• [Physical therapy, dietary modifications, etc.]

Alternative Treatments Considered: [Other treatment options that were considered and why they were not pursued]

Changes to Interventions: [Any modifications to treatment plan]

• Date of change:
• Reason for change:
• New intervention:

Follow-up and Outcomes

Immediate Outcome: [Outcome during hospitalization or initial treatment period]

• Clinical response:
• Laboratory or imaging follow-up:
• Complications:
• Length of hospitalization (if applicable):

Short-term Follow-up: ([Timeframe, e.g., 1 month])

• Clinical status:
• Follow-up tests:
• Adherence to treatment:
• Any issues or concerns:

Long-term Follow-up: ([Timeframe, e.g., 6 months, 1 year])

• Clinical status:
• Recovery or resolution:
• Functional status:
• Quality of life:
• Recurrence or complications:

Patient-Reported Outcomes: [Symptoms, quality of life, patient satisfaction]

Discussion

Paragraph 1: Summary and Significance [Briefly summarize the case and state its significance]

Paragraph 2: Literature Review [Review similar cases in the literature]

• Number of similar cases reported
• Comparison to this case
• What is novel about this case
• [Cite relevant references]

Paragraph 3: Clinical Implications [What can clinicians learn from this case?]

• Recognition of atypical presentations
• Diagnostic pearls
• Treatment considerations
• When to consider this diagnosis

Paragraph 4: Pathophysiology or Mechanism (if applicable) [Explain underlying mechanism, why this occurred, contributing factors]

Paragraph 5: Strengths and Limitations [Acknowledge limitations of case report]

• Single case report limitations
• Cannot establish causation
• Generalizability concerns
• Strengths of comprehensive evaluation

Paragraph 6: Future Directions [Unanswered questions, areas for future research]

Learning Points

• [Point 1: Concise, actionable clinical lesson]
• [Point 2: Key diagnostic or treatment pearl]
• [Point 3: When to consider this diagnosis]
• [Point 4: (optional) Additional takeaway]

Patient Perspective

[Optional but encouraged: Patient's own description of experience, in their own words if possible]

"[Patient quote describing their experience, symptoms, treatment, or outcome]"

[Or narrative description of patient's perspective, impact on quality of life, satisfaction with care]

Informed Consent

Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request.

[OR if patient deceased/unable to consent:]

Written informed consent was obtained from the patient's next of kin for publication of this case report, as the patient was deceased [or unable to provide consent due to...] at the time of manuscript preparation.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Funding

This case report received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

[OR: This work was supported by [funding source and grant number]]

Acknowledgments

[Acknowledge contributors who do not meet authorship criteria, providers who cared for patient, etc.]

References

[Format according to journal requirements - typically AMA, Vancouver, or APA]

1. [First reference - Author(s). Title. Journal. Year;Volume(Issue):Pages.] 2. [Second reference...]

---

CARE Checklist Completion

Use the CARE checklist to ensure all required elements are included:

• [ ] Title includes "case report"
• [ ] Keywords provided (2-5)
• [ ] Structured/unstructured abstract
• [ ] Introduction with background and novelty
• [ ] Patient demographics (de-identified)
• [ ] Clinical findings
• [ ] Timeline
• [ ] Diagnostic assessment
• [ ] Therapeutic interventions
• [ ] Follow-up and outcomes
• [ ] Discussion with literature review
• [ ] Patient perspective (if possible)
• [ ] Informed consent statement
• [ ] All 18 HIPAA identifiers removed
• [ ] References formatted correctly
• [ ] Figures/tables labeled and referenced
• [ ] Word count within journal limits

---

De-identification Checklist

Verify all HIPAA identifiers removed:

• [ ] Names (patient, family, providers)
• [ ] Geographic locations smaller than state
• [ ] Exact dates (use year only or relative time)
• [ ] Phone numbers
• [ ] Email addresses
• [ ] Medical record numbers
• [ ] Account numbers
• [ ] License numbers
• [ ] Device serial numbers
• [ ] URLs
• [ ] IP addresses
• [ ] Biometric identifiers
• [ ] Full-face photos (cropped or blurred)
• [ ] Any other identifying information

---

Notes:

• Adapt this template to your specific journal's requirements
• Check word count limits (typically 1500-3000 words)
• Follow journal's reference style
• Include institutional review/ethics exemption if applicable
• Consider attaching CARE checklist when submitting

Clinical Study Report (CSR) Template

ICH-E3 Format

---

TITLE PAGE

Study Title: [Full descriptive title including compound, indication, phase]

Protocol Number: [Sponsor protocol number] Protocol Version: [Final protocol version and date]

Sponsor: [Company name and address] Compound/Drug Name: [Generic and proprietary names, compound code] Indication: [Therapeutic area and specific indication studied]

Study Phase: [I / II / III / IV] Study Type: [Interventional / Observational]

Report Date: [MM/DD/YYYY] Report Version: [Version number]

Medical Expert: [Name, MD, Title] Biostatistician: [Name, PhD, Title]

Confidentiality Statement: "This document contains confidential information belonging to [Sponsor]. It may not be reproduced or distributed without permission."

---

SYNOPSIS

Title: [Abbreviated title]

Protocol Number: [Number] Study Phase: [Phase] Study Period: [Start date - End date]

Study Objectives

Primary Objective: [State primary objective clearly and concisely]

Secondary Objectives:

• [Secondary objective 1]
• [Secondary objective 2]

Methodology

Study Design: [Randomized, double-blind, placebo-controlled, parallel-group, etc.]

Study Population:

• Target population: [Patient population]
• Key inclusion criteria: [Main criteria]
• Key exclusion criteria: [Main criteria]

Sample Size:

• Planned: [N participants]
• Randomized: [N participants]
• Completed: [N participants]

Treatment:

• Treatment A: [Drug name, dose, route, frequency]
• Treatment B: [Comparator/placebo]
• Treatment duration: [Weeks/months]
• Follow-up duration: [Weeks/months]

Endpoints:

Primary:

• [Primary endpoint definition and timepoint]

Secondary:

• [Secondary endpoint 1]
• [Secondary endpoint 2]

Statistical Methods: [Brief description of analysis approach, significance level, handling of multiplicity]

Results

Participant Disposition:

• Screened: [N]
• Randomized: [N Treatment A, N Treatment B]
• Completed: [N Treatment A, N Treatment B]
• Discontinued: [N overall, % - main reasons]

Demographics and Baseline: [Summary of key baseline characteristics, comparability across groups]

Efficacy Results:

Primary Endpoint:

• [Result for Treatment A vs B, effect size, 95% CI, p-value]

Secondary Endpoints:

• [Results for each secondary endpoint]

Safety Results:

• Any AE: [% Treatment A vs B]
• Treatment-related AE: [% Treatment A vs B]
• Serious AE: [% Treatment A vs B]
• Discontinuations due to AE: [% Treatment A vs B]
• Deaths: [N Treatment A vs B]
• Common AEs (≥5%): [List with percentages]

Conclusions

[Overall conclusions regarding efficacy and safety, benefit-risk assessment]

---

TABLE OF CONTENTS

[Detailed table of contents with page numbers]

---

LIST OF ABBREVIATIONS

---

ETHICS (Section 2)

2.1 Independent Ethics Committee (IEC) or Institutional Review Board (IRB)

[List of all IECs/IRBs that approved the study]

2.2 Ethical Conduct of the Study

This study was conducted in accordance with:

• ICH Good Clinical Practice (GCP) E6(R2)
• Declaration of Helsinki (current version)
• Applicable regulatory requirements
• Sponsor Standard Operating Procedures

2.3 Patient Information and Consent

Informed consent was obtained from all participants before any study-specific procedures. The informed consent process included:

• Written information about study purpose, procedures, risks, and benefits
• Opportunity to ask questions
• Voluntary participation with right to withdraw
• Signatures of participant and person obtaining consent
• Copy provided to participant

---

INVESTIGATORS AND STUDY ADMINISTRATIVE STRUCTURE (Section 3)

3.1 Investigators and Study Centers

[Table listing all investigators, sites, and enrollment]

Coordinating Investigator: [Name, if applicable]

3.2 Study Administrative Structure

Sponsor:

• Medical Monitor: [Name, credentials]
• Project Manager: [Name]
• Biostatistician: [Name, credentials]

Contract Research Organization (CRO): [Name, if applicable]

• [Responsibilities]

3.3 Responsibilities of Parties Involved

[Description of sponsor, investigator, CRO, DSMB responsibilities]

---

INTRODUCTION (Section 4)

4.1 Background

[Detailed background on disease/condition, unmet medical need, treatment landscape]

4.2 Nonclinical Studies

[Summary of relevant preclinical pharmacology, toxicology, and safety findings]

4.3 Previous Clinical Studies

[Summary of prior clinical experience with investigational product]

4.4 Study Rationale and Objectives

[Justification for conducting this study, specific objectives]

---

STUDY OBJECTIVES AND PLAN (Section 5)

5.1 Objectives and Endpoints

Primary Objective: [Objective statement]

Primary Endpoint: [Detailed endpoint definition, measurement method, timepoint]

Secondary Objectives: 1. [Objective] 2. [Objective]

Secondary Endpoints: 1. [Endpoint definition] 2. [Endpoint definition]

5.2 Study Design

[Detailed description of study design with diagram if helpful]

Design Type: [Parallel, crossover, factorial, etc.] Blinding: [Double-blind, open-label, etc.] Randomization: [1:1, 2:1, stratified, etc.] Duration: [Treatment period, follow-up period]

Study Schema: [Flow diagram showing screening, randomization, treatment periods, follow-up]

5.3 Study Population

Key Inclusion Criteria: 1. [Criterion] 2. [Criterion]

Key Exclusion Criteria: 1. [Criterion] 2. [Criterion]

5.4 Treatments

Investigational Product:

• Name: [Generic, trade, code]
• Formulation: [Tablet, capsule, injection]
• Dose: [Dose and regimen]
• Route: [PO, IV, SC, etc.]
• Packaging and labeling: [Description]

Comparator: [Similar details for comparator or placebo]

Concomitant Medications: [Permitted and prohibited medications]

5.5 Sample Size Determination

Target Sample Size: [N per group, N total]

Justification:

• Assumed effect size: [Value]
• Variability (SD): [Value]
• Type I error (α): [0.05]
• Power (1-β): [80% or 90%]
• Expected dropout rate: [%]
• Two-sided test

5.6 Statistical Analysis Plan

Analysis Populations:

• Full Analysis Set (FAS): [Definition]
• Per-Protocol Set (PPS): [Definition]
• Safety Analysis Set: [Definition]

Statistical Methods:

• Primary endpoint: [Method - e.g., ANCOVA with baseline as covariate]
• Secondary endpoints: [Methods]
• Handling of missing data: [Approach]
• Multiplicity adjustment: [Method if applicable]
• Interim analyses: [If planned]

Significance Level: α = 0.05 (two-sided)

---

STUDY PATIENTS (Section 6)

6.1 Disposition of Patients

Participant Flow (CONSORT Diagram):

[Include detailed CONSORT diagram showing screening through analysis]

Summary Table:

6.2 Protocol Deviations

Major Protocol Deviations: [Summary of major deviations, impact on data, subjects affected]

Important Protocol Deviations by Category:

---

(Continues with sections 7-14 following ICH-E3 structure...)

---

Note: This is an abbreviated template. A complete CSR following ICH-E3 is typically 50-300 pages with extensive appendices. Key sections to complete:

• Section 7: Efficacy Evaluation
• Section 8: Safety Evaluation
• Section 9: Discussion and Overall Conclusions
• Section 10: Tables, Figures, and Graphs
• Section 11: References
• Section 12-14: Appendices (Protocol, CRFs, Investigator list, etc.)

Serious Adverse Event (SAE) Report Template

Report Information

Report Type: [ ] Initial Report [ ] Follow-up Report [ ] Final Report Report Number: [SAE-YYYY-####] Report Date: [MM/DD/YYYY] Reporter: [Name and title] Reporter Contact: [Email and phone]

Follow-up Number: [If follow-up: #1, #2, etc.] Previous Report Date: [If follow-up]

---

Study Information

Protocol Number: [Protocol ID] Protocol Title: [Full study title] Study Phase: [ ] Phase I [ ] Phase II [ ] Phase III [ ] Phase IV Study Sponsor: [Sponsor name] IND/IDE Number: [IND or IDE number if applicable] ClinicalTrials.gov ID: [NCT number]

Principal Investigator: [Name] Site Number: [Site ID] Site Name: [Institution name]

---

Subject Information (De-identified)

Subject ID / Randomization Number: [ID only, no name] Subject Initials: [XX] (if permitted by regulatory authority) Age: [Years] OR Date of Birth: [Year only: YYYY] Sex: [ ] Male [ ] Female [ ] Other Race: [Category] Ethnicity: [Hispanic or Latino / Not Hispanic or Latino] Weight: [kg] Height: [cm]

Study Arm / Treatment Group: [ ] Treatment A [ ] Treatment B [ ] Placebo [ ] Blinded

Date of Informed Consent: [MM/DD/YYYY] Date of First Study Drug: [MM/DD/YYYY] Date of Last Study Drug: [MM/DD/YYYY] Study Drug Status at Time of Event: [ ] Ongoing [ ] Completed [ ] Discontinued

---

Adverse Event Information

Reported Term (Verbatim): [Exact term reported by investigator/patient]

MedDRA Coding:

• Preferred Term (PT): [MedDRA PT]
• System Organ Class (SOC): [MedDRA SOC]
• MedDRA Version: [e.g., 25.0]

Event Description: [Detailed narrative description of the adverse event]

Date of Onset: [MM/DD/YYYY] Time of Onset: [HH:MM] (if known and relevant) Date of Resolution: [MM/DD/YYYY] OR [ ] Ongoing Duration: [Days/hours if resolved]

Event Location: [ ] Inpatient [ ] Outpatient [ ] Home [ ] Other: ________

---

Seriousness Criteria

This event is considered serious because it resulted in or required:

• [ ] Death - Date of death: [MM/DD/YYYY]
• [ ] Life-threatening - Immediate risk of death at time of event
• [ ] Hospitalization (initial or prolonged) - Dates: [MM/DD/YYYY to MM/DD/YYYY]
• [ ] Persistent or significant disability/incapacity
• [ ] Congenital anomaly/birth defect
• [ ] Medically important event - Explanation: _________________

Hospitalization Details (if applicable):

• Admission Date: [MM/DD/YYYY]
• Discharge Date: [MM/DD/YYYY] OR [ ] Still hospitalized
• Hospital Name: [Name and location]
• ICU Admission: [ ] Yes [ ] No
• If yes, dates: [MM/DD/YYYY to MM/DD/YYYY]

---

Severity Assessment

Severity (Intensity):

• [ ] Mild - Noticeable but does not interfere with daily activities
• [ ] Moderate - Interferes with daily activities but manageable
• [ ] Severe - Prevents usual daily activities, requires intervention

Note: Severity is not the same as seriousness

---

Outcome

• [ ] Recovered/Resolved - Complete resolution, returned to baseline
• [ ] Recovering/Resolving - Improving but not yet fully resolved
• [ ] Not Recovered/Not Resolved - Ongoing without improvement
• [ ] Recovered/Resolved with Sequelae - Persistent effects remain
• [ ] Fatal - Event resulted in death
• [ ] Unknown - Unable to determine outcome

Date of Final Outcome (if resolved): [MM/DD/YYYY]

---

Causality Assessment

Relationship to Study Drug:

• [ ] Not Related - Clearly due to other cause
• [ ] Unlikely Related - Doubtful connection to study drug
• [ ] Possibly Related - Could be related, but other causes possible
• [ ] Probably Related - More likely related to study drug than other causes
• [ ] Definitely Related - Certain relationship to study drug

Relationship to Study Procedures:

• [ ] Not Related [ ] Unlikely [ ] Possibly [ ] Probably [ ] Definitely

Relationship to Underlying Disease:

• [ ] Not Related [ ] Unlikely [ ] Possibly [ ] Probably [ ] Definitely

Relationship to Concomitant Medications:

• [ ] Not Related [ ] Unlikely [ ] Possibly [ ] Probably [ ] Definitely
• Suspected medication(s): _____________________

Rationale for Causality Assessment: [Detailed explanation of causality determination, including temporal relationship, biological plausibility, dechallenge/rechallenge if applicable, alternative explanations]

---

Expectedness

Is this event expected based on the Investigator's Brochure or protocol?

• [ ] Expected - Listed in IB/protocol with similar characteristics
• [ ] Unexpected - Not listed OR more severe than documented

Reference: [IB version and section, or protocol section]

---

Action Taken with Study Drug

• [ ] No change - Study drug continued at same dose
• [ ] Dose reduced - New dose: ______ (from ______)
• [ ] Dose increased - New dose: ______ (from ______)
• [ ] Drug interrupted - Dates: [MM/DD to MM/DD]
• [ ] Resumed [ ] Not resumed
• [ ] Drug permanently discontinued - Date: [MM/DD/YYYY]
• [ ] Not applicable - Event occurred after study drug discontinued

Dechallenge: [ ] Positive (improved after stopping) [ ] Negative [ ] Not done

Rechallenge: [ ] Positive (recurred after restarting) [ ] Negative [ ] Not done

---

Treatment and Interventions

Treatments Given for This Event:

1. [Medication/Procedure]

• Dose/Details: _________________
• Route: _________________
• Start Date: [MM/DD/YYYY]
• Stop Date: [MM/DD/YYYY] OR [ ] Ongoing
• Response: [ ] Effective [ ] Partially effective [ ] Not effective

2. [Additional treatments]

Hospitalization Interventions:

• [ ] IV fluids
• [ ] Oxygen therapy
• [ ] Mechanical ventilation
• [ ] Surgical intervention - Procedure: ______________
• [ ] ICU care
• [ ] Other: ______________

---

Relevant Medical History

Pre-existing Conditions Relevant to This Event: [List conditions that may be related to the event]

Concomitant Medications at Time of Event:

---

Laboratory and Diagnostic Tests

Relevant Laboratory Values:

Imaging/Diagnostic Studies:

• [Study type] ([Date]): [Key findings]

ECG/Monitoring: [Results if relevant]

---

Detailed Event Narrative

[Comprehensive chronological narrative of the event]

Minimum elements to include:

• Patient demographics and study participation timeline
• Relevant medical history
• Chronological description of event development
• Symptoms, signs, and clinical course
• Diagnostic workup and results
• Treatments administered and response
• Clinical outcome and current status
• Investigator's assessment of causality and reasoning

Example Structure:

A [age]-year-old [sex] with a history of [relevant medical conditions] enrolled in 
Study [protocol] on [date] and was randomized to [treatment arm]. The patient had 
been receiving [study drug] at [dose] for [duration] when, on [date], the patient 
developed [initial symptoms]. 

[Describe progression of symptoms, timeline, clinical findings...]

[Describe diagnostic workup performed and results...]

[Describe treatments given and patient response...]

[Describe outcome and current status...]

The investigator assessed this event as [causality] related to study drug because 
[reasoning]. Alternative explanations include [list alternative causes considered].

---

Investigator Assessment

Investigator's Comments: [Additional relevant information, clinical interpretation, conclusions]

Does this event meet criteria for expedited reporting to regulatory authorities?

• [ ] Yes - Fatal or life-threatening unexpected SAE
• [ ] Yes - Other unexpected SAE
• [ ] No - Expected event

---

Follow-up Information Required

Information Pending (if initial or follow-up report):

• [ ] Final outcome
• [ ] Laboratory results
• [ ] Pathology report
• [ ] Imaging results
• [ ] Autopsy results (if death)
• [ ] Consultant reports
• [ ] Medical records
• [ ] Dechallenge/rechallenge information
• [ ] Other: ______________

Expected Date for Follow-up Report: [MM/DD/YYYY]

---

Regulatory Reporting

Sponsor Safety Assessment: [To be completed by sponsor]

• Expectedness: [ ] Expected [ ] Unexpected
• Relationship: [ ] Related [ ] Not related
• Reportable to FDA/EMA: [ ] Yes [ ] No
• Timeline: [ ] 7-day [ ] 15-day [ ] Annual

IRB Notification:

• Reported to IRB: [ ] Yes [ ] No [ ] Not required
• Date reported: [MM/DD/YYYY]
• IRB determination: _______________

---

Signatures

Investigator Signature:

Name: [Principal Investigator name] Title: [MD, credentials] Signature: ____________________ Date: [MM/DD/YYYY]

I certify that this report is accurate and complete to the best of my knowledge.

---

Sponsor Representative (if applicable):

Name: [Name] Title: [Medical Monitor, Safety Officer] Signature: ____________________ Date: [MM/DD/YYYY]

---

Attachments

• [ ] Relevant laboratory reports
• [ ] Imaging reports
• [ ] Pathology reports
• [ ] Discharge summary
• [ ] Death certificate (if applicable)
• [ ] Autopsy report (if applicable)
• [ ] Consultant notes
• [ ] Other: ______________

---

Distribution List

• [ ] Study Sponsor
• [ ] FDA (if applicable)
• [ ] IRB/IEC
• [ ] Data Safety Monitoring Board (if applicable)
• [ ] Site regulatory files

---

Notes

Regulatory Timeline Requirements:

• Fatal or life-threatening unexpected SAEs: 7 days for preliminary report, 15 days for complete
• Other serious unexpected events: 15 days
• IRB notification: Per institutional policy (typically 5-10 days)

Key Points:

• Complete all sections accurately
• Provide detailed narrative
• Include temporal relationships
• Document all sources of information
• Follow up until event resolved
• Maintain patient confidentiality
• Use only de-identified information

Consultation Note Template

Patient Name: [Last, First] Medical Record Number: [MRN] Date of Birth: [MM/DD/YYYY] Age/Sex: [years, M/F]

Consultation Date: [MM/DD/YYYY] Consultation Time: [HH:MM] Location: [Floor, Room number]

Requesting Service: [Primary team] Requesting Physician: [Name] Consulting Service: [Cardiology, Nephrology, etc.] Consulting Physician: [Name and credentials]

---

Reason for Consultation

[Specific clinical question or reason for consultation]

Example: "Please evaluate and manage acute kidney injury in setting of heart failure exacerbation."

---

History of Present Illness (Focused on Consultation Question)

[Relevant history focused on the consultation question]

[Patient Name] is a [age]-year-old [sex] with a history of [relevant conditions] currently admitted to [service] for [admission diagnosis] who is being consulted for [specific issue].

[Chronological narrative relevant to consultation question]

Timeline of Current Issue:

• [Key events leading to consultation]
• [Current status]
• [Treatments tried]

---

Relevant Past Medical History

1. [Condition relevant to consultation] 2. [Additional relevant conditions]

[Only include history pertinent to consultation question]

---

Current Medications

[List medications relevant to consultation question]

---

Allergies

---

Relevant Social/Family History

[Only include if pertinent to consultation]

---

Review of Systems (Focused)

[Focus on systems relevant to consultation question]

[Relevant system]: [Findings] [Additional relevant systems]: [Findings]

---

Physical Examination

Vital Signs:

• Temperature: _____ °F
• Blood Pressure: _____/_____ mmHg
• Heart Rate: _____ bpm
• Respiratory Rate: _____ breaths/min
• Oxygen Saturation: _____% on [O2 status]
• Weight: _____ kg (if relevant)

General: [Overall appearance, distress level]

[Focused Examination Relevant to Consultation]:

Example for Cardiology Consult:

• Cardiovascular:
• JVP: [cm H2O]
• PMI: [location]
• Heart sounds: [S1, S2, murmurs, gallops, rubs]
• Peripheral pulses: [quality]
• Edema: [location and severity]

Example for Pulmonary Consult:

• Pulmonary:
• Respiratory effort: [description]
• Auscultation: [breath sounds, wheezes, crackles]
• Percussion: [findings]

[Include other relevant systems, may abbreviate or defer non-pertinent systems]

---

Pertinent Laboratory and Imaging Data

Labs ([Date]):

[Include only labs relevant to consultation]

Imaging/Diagnostics:

[Study] ([Date]): [Relevant findings]

ECG ([Date]): [Relevant findings]

Other Studies: [Relevant results]

---

Assessment

Consultant's Assessment of [Specific Problem]:

[Detailed assessment of the consultation question]

Differential Diagnosis: 1. [Most likely diagnosis] - [supporting evidence] 2. [Alternative diagnosis] - [evidence for/against] 3. [Additional considerations]

Severity/Acuity: [Assessment of severity]

Contributing Factors: [What is contributing to the problem]

Prognosis: [Short-term and long-term outlook]

---

Recommendations

[Problem Being Addressed]:

Diagnostic Recommendations: 1. [Specific test] - [Rationale] 2. [Additional studies] - [Why needed]

Therapeutic Recommendations: 1. [Intervention/Medication]:

• [Specific dose, route, frequency]
• [Duration]
• [Rationale]
• [Monitoring parameters]

2. [Additional treatments]

3. [Procedures if recommended]:

• [Procedure name]
• [Indication]
• [Timing]

Monitoring Recommendations:

• [What to monitor]
• [How often]
• [Target parameters]

Follow-up Recommendations:

• [ ] Will follow along as consultant during hospitalization
• [ ] Recommend follow-up in [Specialty] clinic in [timeframe]
• [ ] Recommend re-consultation if [specific circumstances]
• [ ] No further consultation needed unless [conditions]

Additional Recommendations:

• [Lifestyle modifications]
• [Patient education points]
• [Precautions]

Recommendations Summary for Primary Team: [Concise bulleted list of key recommendations that can be quickly reviewed] 1. [Action item 1] 2. [Action item 2] 3. [Action item 3]

---

Consultantdiscussion with Primary Team

Discussed with: [Name, role] Date/Time: [MM/DD/YYYY at HH:MM] Topics discussed: [Key points discussed] Plan agreed upon: [Agreement or modifications]

---

Follow-up Plan

Consultant will:

• [ ] Round daily until [condition met or discharge]
• [ ] Re-evaluate in [X] days
• [ ] Available for questions or changes in clinical status
• [ ] Recommend outpatient follow-up in [timeframe]

Primary team to:

• [ ] Implement above recommendations
• [ ] Notify consultant if [specific circumstances]
• [ ] Monitor [specific parameters]

---

Signature

Consultant: [Name, MD/DO, credentials] Service: [Consulting service] Date/Time: [MM/DD/YYYY at HH:MM] Pager/Contact: [Number] Signature: ____________________

Co-signature (if fellow or resident): Attending: [Name, credentials] Date/Time: [MM/DD/YYYY at HH:MM] Signature: ____________________

---

Template Notes

Key Principles for Consultation Notes:

1. Answer the question: Directly address the specific consultation request 2. Be focused: Include only information relevant to the consultation 3. Be specific: Provide clear, actionable recommendations 4. Be concise: Respect primary team's time 5. Be available: Make follow-up plan clear

Common Consultation Types:

Cardiology:

• Pre-operative risk assessment
• Arrhythmia management
• Heart failure management
• Chest pain evaluation

Nephrology:

• Acute kidney injury
• Chronic kidney disease management
• Electrolyte abnormalities
• Dialysis initiation/management

Infectious Disease:

• Antibiotic selection
• Fever of unknown origin
• Complex infections
• HIV management

Endocrinology:

• Diabetes management
• Thyroid disorders
• Adrenal insufficiency
• Calcium disorders

Psychiatry:

• Capacity assessment
• Depression/anxiety management
• Agitation management
• Substance withdrawal

Pain Management:

• Chronic pain consultation
• Post-operative pain control
• Cancer pain management

Palliative Care:

• Goals of care discussion
• Symptom management
• End-of-life care planning

Tips for Effective Consultations:

• Call the referring provider before seeing patient to clarify question
• Introduce yourself to patient and explain your role
• Review chart thoroughly before examination
• Be respectful of primary team's care
• Make specific recommendations, not vague suggestions
• Document same day as consultation
• Communicate recommendations verbally when appropriate
• Be available for questions
• Follow up consistently if ongoing consultation

Discharge Summary Template

Patient Information

Patient Name: [Last, First] Medical Record Number: [MRN] Date of Birth: [MM/DD/YYYY] Age: [years] Sex: [M/F]

Admission Date: [MM/DD/YYYY] Discharge Date: [MM/DD/YYYY] Length of Stay: [X days]

Admitting Service: [Medicine/Surgery/Cardiology/etc.] Attending Physician: [Name] Primary Care Physician: [Name and contact] Consulting Services: [List specialties that saw patient]

---

Admission Diagnosis

[Primary reason for hospitalization]

Example: "Acute decompensated heart failure"

---

Discharge Diagnoses

[Numbered list, prioritized by clinical significance]

Primary Diagnosis: 1. [Primary diagnosis with ICD-10 code]

Secondary Diagnoses: 2. [Secondary diagnosis with ICD-10 code] 3. [Additional diagnosis with ICD-10 code] 4. [Comorbidity with ICD-10 code]

Example:

1. Acute decompensated heart failure (I50.23)
2. Acute kidney injury on chronic kidney disease stage 3 (N17.9, N18.3)
3. Hypokalemia (E87.6)
4. Type 2 diabetes mellitus (E11.9)
5. Coronary artery disease (I25.10)

---

Hospital Course

[Comprehensive yet concise narrative of hospital stay - can be organized chronologically or by problem]

Chronological Format:

[Date Range or Hospital Day 1-X]:

[Patient Name] was admitted to the [service] service with [chief complaint/presenting problem]. On presentation, patient was [clinical status]. Initial workup revealed [key findings].

[Description of key events, interventions, and response to treatment organized by day or by problem]

Hospital Day 1: [Events and interventions]

Hospital Day 2-3: [Progression, response to treatment]

Hospital Day 4-7: [Continued treatment, consultations, procedures]

Final Hospital Days: [Stabilization, preparation for discharge]

Problem-Based Format (Alternative):

1. [Primary Problem]

• Presentation and initial management
• Diagnostic workup
• Treatment course
• Response and outcome
• Status at discharge

2. [Secondary Problem]

• [Similar structure]

3. [Additional Problems]

Key Events and Interventions

Consultations Obtained:

• [Specialty] consulted on [date] for [reason]: [Recommendations]

Procedures Performed:

• [Procedure name] on [date]: [Indication, findings, complications if any]

Significant Diagnostic Studies:

• [Test/imaging] on [date]: [Key findings relevant to discharge care]

Complications:

• [Any complications that occurred]: [How managed]

---

Procedures Performed During Hospitalization

1. [Procedure name] ([Date])

• Indication: [Why performed]
• Findings: [Key findings]
• Complications: [None / specific complications]

2. [Additional procedures]

---

Hospital Course Summary (Brief Version)

[One paragraph summary suitable for quick reference]

Example:

Mr. [Name] was admitted with acute decompensated heart failure in the setting of 
medication non-adherence. He was diuresed with IV furosemide with net negative 
5 liters over 3 days, with significant improvement in dyspnea and resolution of 
lower extremity edema. Echocardiogram showed EF 30%, similar to prior. Kidney 
function improved to baseline with diuresis. He was transitioned to oral diuretics 
on hospital day 3 and remained stable. Patient was ambulating without dyspnea on 
room air by discharge. Comprehensive heart failure education was provided.

---

Discharge Physical Examination

Vital Signs:

• Temperature: \_\_\_\_\_ °F
• Blood Pressure: \_\_\_\_\_/\_\_\_\_\_ mmHg
• Heart Rate: \_\_\_\_\_ bpm
• Respiratory Rate: \_\_\_\_\_ breaths/min
• Oxygen Saturation: \_\_\_\_\_% on [room air / O2]
• Weight: \_\_\_\_\_ kg (Admission weight: \_\_\_\_\_ kg)

General: [Appearance, distress level]

Cardiovascular: [Heart sounds, edema]

Pulmonary: [Breath sounds, work of breathing]

Abdomen: [Tenderness, bowel sounds, distention]

Extremities: [Edema, pulses]

Neurological: [Mental status, focal deficits]

Wounds/Incisions (if applicable): [Healing status]

---

Pertinent Laboratory and Imaging Results

Discharge Labs ([Date])

Imaging/Diagnostic Studies

[Study name] ([Date]): [Key findings relevant to outpatient management]

---

Discharge Medications

[Complete list with clear indication of changes from admission]

New Medications (Started During Hospitalization)

1. [Medication name] [dose] [route] [frequency]

• Indication: [Why prescribed]
• Duration: [If limited duration]
• Special instructions: [With food, time of day, etc.]

Changed Medications (Dose or Frequency Modified)

2. [Medication name] [NEW dose] [route] [frequency]

• CHANGED FROM: [Previous dose and frequency]
• Reason for change: [Why modified]

Continued Medications (No change from home medications)

3. [Medication name] [dose] [route] [frequency]

• CONTINUED from home regimen

Discontinued Medications (Stopped During Hospitalization)

4. [Medication name] - DISCONTINUED

• Reason: [Why stopped]

Complete Medication List for Patient

[Consolidated list in simple format for patient]

1. Furosemide 40 mg by mouth once daily [NEW - for fluid management]
2. Carvedilol 12.5 mg by mouth twice daily [CONTINUED]
3. Lisinopril 20 mg by mouth once daily [CONTINUED]
4. Metformin 1000 mg by mouth twice daily [CONTINUED]
5. Aspirin 81 mg by mouth once daily [CONTINUED]

---

Discharge Condition

Overall Status: [Stable / Improved / Baseline / Requires continued care]

Specific Assessments:

• Hemodynamic status: [Stable]
• Respiratory status: [Room air / Oxygen requirement]
• Mental status: [Alert and oriented x3 / Other]
• Functional status: [Ambulatory / Requires assistance / Bedbound]
• Pain control: [Adequate / Inadequate]
• Wound healing (if applicable): [Appropriate / Delayed]

Example:

Patient is hemodynamically stable, ambulatory without assistance, no supplemental 
oxygen requirement, euvolemic on physical exam, pain well-controlled, and has 
returned to baseline functional status.

---

Discharge Disposition

[Where patient is going after hospital discharge]

Options:

• Home with self-care
• Home with home health services
• Skilled nursing facility
• Acute rehabilitation facility
• Long-term acute care hospital
• Hospice (home or facility)
• Left against medical advice (AMA)
• Transferred to another acute care facility

Discharge Disposition: [Selection from above]

Services Arranged:

• [ ] Home health nursing
• [ ] Physical therapy
• [ ] Occupational therapy
• [ ] Durable medical equipment: [List items]
• [ ] Home oxygen: [Flow rate and delivery method]
• [ ] Other: [Specify]

---

Follow-Up Appointments

1. [Specialty/PCP] with Dr. [Name]

• Date/Time: [Scheduled date and time] OR [Within X days/weeks]
• Location: [Clinic name and address]
• Phone: [Contact number]
• Purpose: [What needs to be addressed]

2. [Additional appointments]

Pending Studies/Labs at Discharge

• [Test name]: [When due, where to go, reason]
• Results will be sent to: [Provider name]

Referrals Placed

• [Specialty]: [Reason for referral, contact information]

---

Patient Instructions

Activity

• [Specific activity restrictions or recommendations]
• Example: "Resume normal activities as tolerated. Avoid heavy lifting >10 lbs for 2 weeks."

Diet

• [Dietary restrictions or recommendations]
• Example: "Low sodium diet (less than 2 grams per day). Fluid restriction to 2 liters per day."

Wound Care (if applicable)

• [Incision care instructions]
• [Dressing change frequency]
• [When stitches/staples should be removed]

Self-Monitoring

• [What patient should monitor at home]
• Example: "Weigh yourself every morning. Call doctor if weight gain >2 lbs in 1 day or >5 lbs in 1 week."

Equipment/Supplies

• [Equipment provided or prescribed]
• [How to use]

Medications

• [General medication instructions]
• [Importance of compliance]
• [What to do if dose missed]

---

Return Precautions / Warning Signs

Call your doctor or return to emergency department if you experience:

• [Specific warning signs relevant to condition]
• [When to seek immediate care vs. call doctor]

Example for heart failure:

- Worsening shortness of breath or difficulty breathing
- Chest pain or pressure
- Severe swelling in legs or abdomen
- Weight gain more than 2 lbs in one day or 5 lbs in one week
- Dizziness, lightheadedness, or fainting
- Fever >101°F
- Any other concerning symptoms

Emergency Contact Numbers:

• Primary care physician: [Phone]
• Specialty clinic: [Phone]
• After-hours nurse line: [Phone]
• 911 for emergencies

---

Patient Education Provided

Topics discussed with patient and/or family:

• [ ] Disease process and prognosis
• [ ] Medication purpose, dosing, and side effects
• [ ] Warning signs and when to seek care
• [ ] Activity and dietary restrictions
• [ ] Follow-up appointments
• [ ] Use of medical equipment
• [ ] [Other specific topics]

Patient/Family Understanding: [Patient and family verbalize understanding of discharge instructions / Teach-back method used and patient able to repeat key points / Interpreter used]

Written Materials Provided:

• [ ] Discharge instructions
• [ ] Medication list
• [ ] Disease-specific education materials
• [ ] Emergency contact information
• [ ] Appointment information

---

Code Status at Discharge

Code Status: [Full code / DNR / DNI / Other limitations]

[If changed during hospitalization, note when and why]

---

Additional Information

Advance Directives

• [ ] Advance directive on file
• [ ] Healthcare proxy designated: [Name and contact]
• [ ] Living will present

Social Situation

[Relevant social factors affecting discharge plan]

• Living situation: [Lives alone / with family / assisted living]
• Caregiver support: [Available / Limited / None]
• Transportation: [Adequate / Needs assistance]
• Barriers to compliance: [Financial / Cognitive / Language / Other]

Pending Issues at Discharge

[Tests or consultations still pending that require outpatient follow-up]

---

Signature

Prepared by: [Physician name, credentials] [Pager/Contact number]

Cosigned by (if resident/fellow): [Attending physician name]

Date and Time: [MM/DD/YYYY at HH:MM]

Electronically signed: [Yes/No]

---

Template Completion Checklist

• [ ] All discharge diagnoses listed with ICD-10 codes
• [ ] Hospital course summarized clearly
• [ ] All procedures documented
• [ ] Discharge medications reconciled and clearly marked (new/changed/continued/stopped)
• [ ] Follow-up appointments scheduled or timeframe provided
• [ ] Patient education documented
• [ ] Return precautions specific to patient's conditions
• [ ] Pending tests/results documented with follow-up plan
• [ ] Code status documented
• [ ] Completed within 24-48 hours of discharge (institutional requirement)
• [ ] Sent to primary care physician and relevant specialists
• [ ] Copy provided to patient

---

Notes

Timing Requirements:

• CMS requires completion within 30 days
• Many hospitals require 24-48 hours
• Should be available for follow-up appointments

Distribution:

• Send to primary care physician
• Send to referring physician
• Send to consulting specialists involved in care
• Provide copy to patient
• Upload to shared HIE (Health Information Exchange)

Quality Measures:

• Medication reconciliation required
• Clear communication of changes
• Specific follow-up plans
• Patient education documented

HIPAA Compliance Checklist for Clinical Reports

18 HIPAA Identifiers - De-identification Checklist

Verify that ALL of the following identifiers have been removed or altered:

• [ ] 1. Names - Patient name, family members, healthcare providers (unless necessary and consented)

• [ ] 2. Geographic subdivisions smaller than state
• No street addresses
• No cities (unless >20,000 population and part of ZIP can be kept if >20,000)
• No counties
• First 3 digits of ZIP code acceptable only if geographic unit >20,000 people
• All other portions of ZIP codes removed

• [ ] 3. Dates (except year)
• No exact dates of birth (year only acceptable; year of birth for those >89 must be aggregated)
• No admission dates
• No discharge dates
• No dates of service
• No dates of death
• Use relative time periods (e.g., "3 months prior") or years only

• [ ] 4. Telephone numbers
• No phone numbers of any kind
• Including patient, family, provider contact numbers

• [ ] 5. Fax numbers
• No fax numbers

• [ ] 6. Email addresses
• No email addresses for patient or related individuals

• [ ] 7. Social Security numbers
• No SSN or partial SSN

• [ ] 8. Medical record numbers
• No MRN, hospital ID, or clinic numbers
• Use coded study ID or case number if needed

• [ ] 9. Health plan beneficiary numbers
• No insurance ID numbers
• No policy numbers

• [ ] 10. Account numbers
• No billing account numbers
• No financial account information

• [ ] 11. Certificate/license numbers
• No driver's license numbers
• No professional license numbers (unless for author credentials)

• [ ] 12. Vehicle identifiers and serial numbers
• No license plate numbers
• No VIN numbers

• [ ] 13. Device identifiers and serial numbers
• No pacemaker serial numbers
• No implant device serial numbers
• Generic device description acceptable (e.g., "implantable cardioverter-defibrillator")

• [ ] 14. Web URLs
• No personal websites
• No URLs identifying individuals

• [ ] 15. IP addresses
• No IP addresses

• [ ] 16. Biometric identifiers
• No fingerprints
• No voiceprints
• No retinal scans
• No other biometric data

• [ ] 17. Full-face photographs and comparable images
• No full-face photographs without consent
• Crop or blur faces if showing
• Remove identifying features (jewelry, tattoos, birthmarks if not clinically relevant)
• Black bars over eyes NOT sufficient
• Ensure no reflection or background identification

• [ ] 18. Any other unique identifying characteristic or code
• No unique characteristics that could identify individual
• No rare disease combinations that could identify
• Consider if combination of remaining data points could identify individual

---

Additional De-identification Considerations

Ages and Dates

• [ ] Patients aged ≤89: Exact age or age range acceptable
• [ ] Patients aged >89: Must be aggregated to "90 or older" or ">89 years"
• [ ] Dates: Use only years OR use relative time periods
• Example: "3 months prior to presentation" instead of "on January 15, 2023"
• Example: "admitted in 2023" instead of "admitted on March 10, 2023"

Geographic Information

• [ ] State or country is acceptable
• [ ] Removed specific cities (unless population >20,000 and no other identifying information)
• [ ] Removed hospital/clinic names
• [ ] Use general descriptors: "a community hospital in the Midwest" or "a tertiary care center"

Rare Conditions and Combinations

• [ ] Consider if very rare disease alone could identify patient
• [ ] Consider if combination of:
• Age + diagnosis + geographic area + timeframe could identify patient
• [ ] May need to be vague about certain unique details
• [ ] Balance between providing clinical information and protecting privacy

Images and Figures

• [ ] All patient identifiers removed from image headers/metadata
• [ ] DICOM data stripped
• [ ] Dates removed from images
• [ ] Medical record numbers removed
• [ ] Faces cropped, blurred, or obscured
• [ ] Identifying marks removed or obscured:
• Tattoos
• Jewelry
• Birthmarks or unique scars (if not clinically relevant)
• [ ] Scale bars and annotations do not contain identifying information
• [ ] Background environment de-identified (room numbers, nameplates, etc.)

Voice and Video

• [ ] No audio recordings with patient voice (unless consent obtained)
• [ ] No video showing identifiable features (unless consent obtained)
• [ ] If video necessary, face must be obscured

---

Informed Consent Checklist (for Case Reports/Publications)

Consent Requirements

• [ ] Informed consent obtained BEFORE publication submission
• [ ] Consent obtained from patient directly (if capable)
• [ ] If patient deceased or incapacitated, consent from legal representative or next of kin
• [ ] For pediatric cases, parental/guardian consent obtained

Consent Form Elements

The informed consent form must include:

• [ ] Purpose of publication (education, medical knowledge)
• [ ] What will be published (case details, images, outcomes)
• [ ] Journal or publication venue (if known)
• [ ] Open access vs. subscription (public availability)
• [ ] De-identification efforts explained
• [ ] Potential for re-identification acknowledged
• [ ] No effect on clinical care
• [ ] Right to withdraw consent (timing limitations)
• [ ] Contact information for questions
• [ ] Patient signature and date
• [ ] Witness signature (if required)

Consent Documentation

• [ ] Signed consent form on file
• [ ] Copy provided to patient
• [ ] Consent available for editor review
• [ ] Statement in manuscript confirming consent obtained

Example statement for manuscript: "Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request."

---

Safe Harbor vs. Expert Determination

Safe Harbor Method

• [ ] All 18 identifiers removed
• [ ] No actual knowledge that remaining information could identify individual
• [ ] Most straightforward method
• [ ] Recommended for most clinical reports

Expert Determination Method

• [ ] Qualified statistician/expert determined very small re-identification risk
• [ ] Methodology documented
• [ ] Analysis methods specified
• [ ] Conclusion documented
• [ ] May allow retention of some data elements
• [ ] Requires statistical expertise

Method used: [ ] Safe Harbor [ ] Expert Determination

---

Minimum Necessary Standard

Use and Disclosure

• [ ] Only minimum PHI necessary for purpose is used
• [ ] Purpose of disclosure clearly defined
• [ ] Limited to relevant information only
• [ ] Consider de-identified data or limited data set as alternatives

Exceptions to Minimum Necessary

Minimum necessary does NOT apply to:

• Treatment purposes (providers may need full information)
• Patient-authorized disclosures
• Disclosures required by law
• Disclosures to HHS for compliance investigation

---

Authorization for Use/Disclosure of PHI

When Authorization Required

Authorization needed for:

• [ ] Research (unless IRB waiver granted)
• [ ] Marketing purposes
• [ ] Sale of PHI
• [ ] Psychotherapy notes
• [ ] Uses beyond treatment, payment, operations (TPO)

Authorization Elements

If authorization required, it must include:

• [ ] Specific description of PHI to be used/disclosed
• [ ] Person(s) authorized to make disclosure
• [ ] Person(s) to receive information
• [ ] Purpose of disclosure
• [ ] Expiration date or event
• [ ] Right to revoke and how
• [ ] Right to refuse to sign
• [ ] Potential for re-disclosure by recipient
• [ ] Patient signature and date

---

Limited Data Set

Limited Data Set Option

A limited data set removes 16 of 18 identifiers but may retain:

• [ ] Dates (admission, discharge, service, birth, death)
• [ ] Geographic information (city, state, ZIP code)

Requirements for Limited Data Set

• [ ] Data Use Agreement (DUA) required
• [ ] DUA specifies permitted uses
• [ ] Only for research, public health, or healthcare operations
• [ ] Recipient agrees not to re-identify
• [ ] Recipient agrees to safeguard data

---

Security Safeguards Checklist

Administrative Safeguards

• [ ] Security management process in place
• [ ] Workforce security measures
• [ ] Access management (role-based)
• [ ] Security training for workforce
• [ ] Incident response procedures

Physical Safeguards

• [ ] Facility access controls
• [ ] Workstation use policies
• [ ] Workstation security measures
• [ ] Device and media controls
• [ ] Secure disposal procedures

Technical Safeguards

• [ ] Access controls (unique user IDs, passwords)
• [ ] Audit controls and logging
• [ ] Integrity controls
• [ ] Transmission security (encryption)
• [ ] Automatic logoff after inactivity

---

Breach Notification Checklist

If Unauthorized Disclosure Occurs

• [ ] Determine if breach occurred (unauthorized access/use/disclosure)
• [ ] Assess risk of harm to individual
• [ ] If breach affects <500 individuals:
• Notify individual within 60 days
• Report to HHS annually
• [ ] If breach affects ≥500 individuals:
• Notify individuals within 60 days
• Notify HHS within 60 days
• Notify media if affects ≥500 in a state/jurisdiction
• [ ] Document breach and response
• [ ] Implement corrective action

Breach Notification Content

Notification must include:

• [ ] Description of breach
• [ ] Types of information involved
• [ ] Steps individuals should take
• [ ] What organization is doing
• [ ] Contact for questions

---

Research-Specific Compliance

IRB/Privacy Board Considerations

• [ ] IRB approval obtained (if research)
• [ ] HIPAA authorization obtained OR waiver granted
• [ ] Waiver justification documented:
• Minimal risk to privacy
• Research cannot practically be conducted without waiver
• Research cannot practically be conducted without PHI
• Plan to protect identifiers
• Plan to destroy identifiers when appropriate

Clinical Trial Reporting

• [ ] Subject identified by ID number only
• [ ] No names in regulatory submissions
• [ ] Initials only if required by regulatory authority
• [ ] Dates limited to year or relative time
• [ ] Protocol includes privacy protections

---

Special Populations

Pediatric Cases

• [ ] Parent/guardian consent obtained
• [ ] Child assent obtained (if age-appropriate)
• [ ] Extra care with identifiable photos
• [ ] School information removed

Deceased Patients

• [ ] HIPAA protections apply for 50 years post-death
• [ ] Next of kin consent for publication
• [ ] Autopsy information de-identified

Mental Health and Substance Abuse

• [ ] Extra protections under 42 CFR Part 2
• [ ] Explicit consent for disclosure
• [ ] Cannot re-disclose without consent

---

Final Compliance Verification

Reviewed by: ____________________ Date: ____________________ Signature: ____________________

Compliance Status: [ ] Compliant [ ] Needs revision [ ] Not compliant

Issues identified: 1. [Issue] 2. [Issue]

Corrective actions: 1. [Action] 2. [Action]

Re-review required: [ ] Yes [ ] No Re-review date: ____________________

---

Documentation to Maintain

Keep on file:

• [ ] Signed patient consent (if applicable)
• [ ] IRB approval (if research)
• [ ] HIPAA waiver (if applicable)
• [ ] De-identification verification
• [ ] Data use agreement (if limited data set)
• [ ] Authorization forms (if applicable)
• [ ] Training records for personnel handling PHI
• [ ] Audit logs

Retention period: Minimum 6 years per HIPAA requirement

History and Physical Examination (H&P) Template

Patient Name: [Last, First] Medical Record Number: [MRN] Date of Birth: [MM/DD/YYYY] Age: [years] Sex: [M/F]

Date of Admission/Encounter: [MM/DD/YYYY] Time: [HH:MM] Location: [Hospital floor, Clinic, ED] Admitting Service: [Medicine, Surgery, etc.] Attending Physician: [Name]

---

Chief Complaint (CC)

"[Patient's stated reason for seeking care, in quotes]"

---

History of Present Illness (HPI)

[Patient Name] is a [age]-year-old [sex] with a history of [relevant PMHx] who presents with [chief complaint].

[Use OPQRST format for symptoms, provide chronological narrative]

Onset: [When did symptoms start? Sudden vs gradual onset?] Location: [Where? Does it radiate?] Duration: [How long?] Character: [Quality - sharp, dull, pressure, etc.] Aggravating factors: [What makes it worse?] Relieving factors: [What makes it better?] Timing: [Constant or intermittent? Pattern?] Severity: [0-10 scale for pain, functional impact] Associated symptoms: [Other symptoms?]

Prior evaluations and treatments: Why presenting now:

---

Past Medical History (PMH)

1. [Condition] - diagnosed [year], [current status] 2. [Condition] - diagnosed [year], [treatment] 3. [Additional conditions]

[ ] No known medical problems

---

Past Surgical History (PSH)

1. [Procedure] ([year]) - [indication, complications if any] 2. [Procedure] ([year])

[ ] No prior surgeries

---

Medications

[ ] No current medications

---

Allergies

[ ] No known drug allergies (NKDA)

---

Family History (FH)

• Father: [Age/deceased at age X], [medical conditions]
• Mother: [Age/deceased at age X], [medical conditions]
• Siblings: [Number], [relevant conditions]
• Children: [Number], [relevant conditions]

[Note hereditary conditions relevant to patient's presentation]

[ ] Non-contributory

---

Social History (SH)

Tobacco: [Current/former/never], [pack-years if applicable] Alcohol: [Frequency and amount, CAGE questions if indicated] Illicit drugs: [Current/former/never, type, route] Occupation: [Current or former occupation] Living situation: [Lives alone/with family, housing type] Marital status: [Single/married/divorced/widowed] Sexual history: [If relevant] Exercise: [Type and frequency] Diet: [General diet description] Functional status: [ADL independence, baseline activity level]

---

Review of Systems (ROS)

[Systematic review - check relevant systems]

Constitutional: [ ] Fever [ ] Chills [ ] Night sweats [ ] Weight loss [ ] Weight gain [ ] Fatigue Eyes: [ ] Vision changes [ ] Eye pain [ ] Discharge ENT: [ ] Hearing loss [ ] Tinnitus [ ] Sinus problems [ ] Sore throat Cardiovascular: [ ] Chest pain [ ] Palpitations [ ] Edema [ ] Orthopnea [ ] PND [ ] Claudication Respiratory: [ ] Dyspnea [ ] Cough [ ] Wheezing [ ] Hemoptysis Gastrointestinal: [ ] Nausea [ ] Vomiting [ ] Diarrhea [ ] Constipation [ ] Abdominal pain [ ] Melena [ ] Hematochezia Genitourinary: [ ] Dysuria [ ] Frequency [ ] Urgency [ ] Hematuria [ ] Incontinence Musculoskeletal: [ ] Joint pain [ ] Swelling [ ] Stiffness [ ] Back pain [ ] Weakness Skin: [ ] Rash [ ] Lesions [ ] Itching [ ] Changes in moles Neurological: [ ] Headache [ ] Dizziness [ ] Syncope [ ] Seizures [ ] Weakness [ ] Numbness [ ] Tingling Psychiatric: [ ] Depression [ ] Anxiety [ ] Sleep disturbance Endocrine: [ ] Heat/cold intolerance [ ] Polyuria [ ] Polydipsia [ ] Polyphagia Hematologic/Lymphatic: [ ] Easy bruising [ ] Bleeding [ ] Lymph node swelling Allergic/Immunologic: [ ] Seasonal allergies [ ] Frequent infections

All other systems reviewed and negative [ ]

---

Physical Examination

Vital Signs:

• Temperature: _____ °F (oral/axillary/tympanic)
• Blood Pressure: _____/_____ mmHg ([right arm, sitting])
• Heart Rate: _____ bpm (regular/irregular)
• Respiratory Rate: _____ breaths/min
• Oxygen Saturation: _____% on [room air / O2 at ___ L/min]
• Height: _____ cm / inches
• Weight: _____ kg / lbs
• BMI: _____ kg/m²
• Pain Score: ___/10

General: [Overall appearance, apparent vs stated age, nutritional status, distress level]

HEENT:

• Head: [Normocephalic, atraumatic, scalp lesions]
• Eyes: [PERRLA, EOMI, conjunctiva, sclera, fundoscopy if done]
• Ears: [TMs, canals, hearing]
• Nose: [Nares, septum, discharge, sinus tenderness]
• Throat: [Oropharynx, tonsils, dentition, mucosa]

Neck: [Supple/stiff, lymphadenopathy, thyroid, JVP, carotid bruits]

Cardiovascular:

• Inspection: [PMI, precordial movement]
• Palpation: [PMI location, thrills, lifts]
• Auscultation: [Rate, rhythm, S1/S2, murmurs/rubs/gallops, location and radiation]
• Peripheral pulses: [Radial, femoral, DP, PT - rate quality bilaterally]
• Extremities: [Edema, cyanosis, clubbing]

Pulmonary:

• Inspection: [Respiratory effort, use of accessory muscles, chest wall deformities]
• Palpation: [Tactile fremitus, chest expansion]
• Percussion: [Resonance, dullness]
• Auscultation: [Breath sounds, adventitious sounds - location and quality]

Abdomen:

• Inspection: [Contour, scars, distention, visible peristalsis]
• Auscultation: [Bowel sounds - present, hyperactive, hypoactive, absent]
• Percussion: [Tympany, dullness, liver span, spleen]
• Palpation: [Soft/firm, tenderness, masses, organomegaly, rebound, guarding, Murphy's sign]

Musculoskeletal:

• Inspection: [Deformities, swelling, erythema]
• Palpation: [Tenderness, warmth]
• Range of motion: [Active and passive, limitations]
• Strength: [5-point scale by major muscle groups]
• Gait: [Normal, antalgic, ataxic, spastic]

Skin: [Color, temperature, moisture, turgor, lesions, rashes, wounds]

Neurological:

• Mental Status: [Alert, oriented x3 (person, place, time), speech, memory]
• Cranial Nerves: [II-XII - document abnormalities]
• Motor: [Strength 5-point scale, tone, bulk, fasciculations]
• Sensory: [Light touch, pinprick, proprioception, vibration]
• Reflexes: [Deep tendon reflexes 0-4+ scale, Babinski]
• Coordination: [Finger-to-nose, heel-to-shin, rapid alternating movements]
• Gait: [Already documented above or describe here]

Psychiatric: [Mood, affect, thought process, thought content, judgment, insight]

Genitourinary: (if applicable) [Defer/document findings if examined]

Rectal: (if applicable) [Defer/document findings if examined]

---

Laboratory and Imaging Results

[Include relevant results available at time of H&P]

Labs ([Date]):

Imaging ([Study], [Date]): [Key findings]

ECG ([Date]): [Rate, rhythm, intervals, axis, ST-T changes, other findings]

Other Studies:

---

Assessment and Plan

Assessment:

[Patient summary statement in one sentence]

Problem List:

1. [Primary Problem/Diagnosis] ([ICD-10 code])

Assessment: [Brief description of problem, severity, stability]

Plan:

• Diagnostics: [Labs, imaging, consultations needed]
• Therapeutics: [Medications, procedures, interventions]
• [Medication]: [dose, route, frequency] for [indication]
• Monitoring: [What to monitor, how often]
• Follow-up: [When and with whom]
• Disposition: [Admit to floor/ICU, discharge, observation]

2. [Secondary Problem] ([ICD-10 code])

Assessment: [Description]

Plan:

• [Diagnostics]
• [Therapeutics]
• [Monitoring]

3. [Additional Problems] [Continue for all active problems]

Code Status: [Full code / DNR / DNI / Other]

Prophylaxis:

• DVT prophylaxis: [Pharmacologic and/or mechanical]
• GI prophylaxis: [If indicated]
• Aspiration precautions: [If indicated]

Disposition: [Admit to service, location (floor/ICU), level of care]

---

Signature

Physician: [Name, credentials] Level: [Intern, Resident, Attending] Date/Time: [MM/DD/YYYY at HH:MM] Signature: ____________________

Co-signature (if applicable): Attending: [Name, credentials] Date/Time: [MM/DD/YYYY at HH:MM] Signature: ____________________

---

Template Completion Checklist

• [ ] Chief complaint documented
• [ ] HPI comprehensive (≥4 HPI elements for billing)
• [ ] PMH reviewed
• [ ] Medications reconciled
• [ ] Allergies documented
• [ ] ROS performed (≥10 systems for comprehensive)
• [ ] Complete physical exam documented (≥8 systems for comprehensive)
• [ ] Labs/imaging reviewed
• [ ] Assessment and plan for each problem
• [ ] Code status documented
• [ ] Prophylaxis addressed
• [ ] Disposition clear
• [ ] Completed within 24 hours of admission (TJC requirement)
• [ ] Signed and dated

Laboratory Report Template

Patient Information

Patient Name: [Last, First] Medical Record Number: [MRN] Date of Birth: [MM/DD/YYYY] Age/Sex: [Age years, M/F]

Ordering Physician: [Name] Location: [Inpatient unit / Outpatient clinic]

---

Specimen Information

Specimen Type: [Blood / Serum / Plasma / Urine / CSF / Other] Collection Date/Time: [MM/DD/YYYY at HH:MM] Received Date/Time: [MM/DD/YYYY at HH:MM] Reported Date/Time: [MM/DD/YYYY at HH:MM]

Accession Number: [Lab accession number] Specimen Condition: [Acceptable / See comments] Fasting Status: [Fasting / Non-fasting / Unknown] (if relevant)

---

Laboratory Results

Example: Complete Blood Count (CBC)

Differential:

Example: Basic Metabolic Panel (BMP)

---

Interpretation / Comments

[Clinical interpretation when applicable]

Example for Anemia:

Normocytic anemia with elevated WBC. Differential diagnosis includes anemia of chronic 
disease, recent blood loss, or hemolysis. Consider reticulocyte count, iron studies, 
and peripheral smear for further evaluation. Clinical correlation recommended.

Example for Electrolyte Abnormality:

Hypokalemia detected (K+ 3.2 mEq/L). Common causes include diuretic use, GI losses, or 
inadequate intake. Recommend potassium repletion and follow-up testing. Moderate 
azotemia present, consistent with acute kidney injury or chronic kidney disease. 
Clinical correlation with patient history and prior results recommended.

---

Critical Values

[If any results meet criteria for critical values]

Critical Result: [Test name] = [Value] [Units] Reference Range: [Normal range] Significance: [Life-threatening, requires immediate action]

Notification:

• Called to: [Name and title of person notified]
• Date/Time: [MM/DD/YYYY at HH:MM]
• Read-back verified: [Yes]
• Notified by: [Lab personnel name]

Example Critical Values:

• Glucose <40 mg/dL or >500 mg/dL
• Potassium <2.5 mEq/L or >6.5 mEq/L
• Sodium <120 mEq/L or >160 mEq/L
• Hemoglobin <5.0 g/dL
• Platelets <20 × 10³/μL
• WBC <1.0 × 10³/μL or >50 × 10³/μL
• INR >5.0 (on warfarin)
• Positive blood culture
• Positive CSF Gram stain

---

Quality Control

Specimen Quality: [Acceptable / See note]

QC Notes:

• [X] Specimen collected in appropriate tube
• [X] Specimen adequately labeled
• [X] Specimen volume sufficient
• [X] No hemolysis, lipemia, or icterus
• [X] Specimen processed within acceptable time

Issues (if any):

• [ ] Hemolyzed - may affect [specific tests]
• [ ] Clotted - unable to perform coagulation studies
• [ ] Insufficient volume - limited testing performed
• [ ] Delayed processing - stability concerns for [specific analytes]

---

Methodology

Test Method: [Instrumentation and methodology]

Examples:

• CBC: Automated cell counter (Sysmex XN-1000)
• Chemistry: Spectrophotometry (Beckman AU5800)
• Glucose: Enzymatic assay, hexokinase method
• HbA1c: HPLC (high-performance liquid chromatography)
• Troponin: High-sensitivity immunoassay
• Drug levels: Liquid chromatography-mass spectrometry (LC-MS/MS)

---

Special Tests Examples

Hemoglobin A1c

Reference Ranges:

• Non-diabetic: 4.0-5.6%
• Prediabetes: 5.7-6.4%
• Diabetes diagnosis: ≥6.5%
• Treatment target: <7% (individualized)

Lipid Panel

Coagulation Studies

Therapeutic Ranges (INR):

• Atrial fibrillation: 2.0-3.0
• Mechanical heart valve: 2.5-3.5
• DVT/PE treatment: 2.0-3.0

Thyroid Function Tests

Interpretation: Findings consistent with primary hypothyroidism

Urinalysis

Physical Examination:

• Color: [Yellow / Amber / Other]
• Clarity: [Clear / Cloudy / Turbid]
• Specific Gravity: [1.005-1.030]

Chemical Examination:

Microscopic Examination (if indicated):

• WBCs: [number] /hpf (normal <5)
• RBCs: [number] /hpf (normal <3)
• Epithelial cells: [Few/Moderate/Many]
• Bacteria: [None/Few/Moderate/Many]
• Casts: [Type and number]
• Crystals: [Type if present]

---

Microbiology Report Format

Culture Results

Specimen Source: [Blood / Urine / Sputum / Wound / Other] Collection: [Date and time]

Gram Stain: [Results of Gram stain if performed] Example: "Many Gram-positive cocci in clusters, many WBCs"

Culture Results:

Organism: [Identified organism] Quantity: [Light / Moderate / Heavy growth] or [CFU count]

Antimicrobial Susceptibility Testing:

Example:

Interpretation: S = Susceptible, I = Intermediate, R = Resistant

---

Molecular/Genetic Testing

Test: [Specific test name] Method: [PCR / Sequencing / Array / Other] Result: [Detected / Not detected / Variant identified]

Interpretation: [Clinical significance of result]

---

Reference Laboratory Results

[For send-out tests]

Test: [Name] Performed by: [Reference lab name and location] Result: [Value] Reference Range: [Range] Method: [Methodology] Reported: [Date]

---

Laboratory Director Signature

Medical Director: [Name, MD] [Board Certifications] [CLIA License Number]

Electronically signed: [Date]

---

LOINC Codes (for interoperability)

[LOINC codes for each test when applicable for electronic reporting]

Example:

• Hemoglobin: 718-7
• Glucose: 2345-7
• Creatinine: 2160-0
• TSH: 3016-3

Surgical Pathology Report Template

Patient and Specimen Information

Patient Name: [Last, First] Medical Record Number: [MRN] Date of Birth: [MM/DD/YYYY] Age: [years] Sex: [M/F]

Accession Number: [PathologyAccessionNumber] Specimen Received: [Date and time] Report Date: [Date]

Ordering Physician: [Name] Clinical Service: [Department]

---

Specimen(s) Submitted

Specimen A: [Description of specimen] Example: "Skin, left forearm, excisional biopsy"

Specimen B: [If multiple specimens]

---

Clinical History / Indication

[Relevant clinical information provided by clinician]

Example: "72-year-old woman with enlarging pigmented lesion on left forearm. Clinical concern for melanoma. Previous biopsy showed atypical melanocytic proliferation."

---

Gross Description

Specimen A labeled "[Specimen label]":

Description:

• Received [fresh/in formalin]
• Consists of [specimen type] measuring [dimensions in cm]
• [External surface description]
• [Cut surface/sectioning description]
• [Lesion description if applicable]
• [Orientation markers if present]
• [Inking for margins]

Sampling:

• [How specimen was sectioned]
• [Cassette labeling]
• [Percent of tissue submitted]

Example:

Specimen A labeled "Skin, left forearm, excisional biopsy":
Received fresh is an oriented ellipse of skin measuring 3.5 x 1.2 x 0.8 cm with a 
suture indicating superior. The epidermis contains a 1.1 cm diameter irregularly 
pigmented lesion located 1.5 cm from superior, 1.2 cm from inferior, 0.8 cm from  
medial, and 1.2 cm from lateral margins. Inking: superior blue, inferior black, 
medial green, lateral red, deep yellow. Serially sectioned perpendicular to long 
axis into 10 slices. Entirely submitted in cassettes A1-A4.

---

Microscopic Description

[Detailed histological findings]

Architecture: [Structural patterns observed]

Cytology: [Cell type, nuclear features, cytoplasm, pleomorphism]

Special Features: [Necrosis, mitoses, invasion, margins]

Stains/Immunohistochemistry Results: [Results of special stains or immunostains]

Example:

Sections show skin with an asymmetric melanocytic proliferation composed of 
epithelioid and spindled melanocytes arranged in irregular nests at the 
dermoepidermal junction with extension into the papillary and reticular dermis.
Melanocytes show marked cytologic atypia with nuclear enlargement, hyperchromasia,
and prominent nucleoli. Mitotic activity is present with 4 mitoses per mm². 
No ulceration identified. The lesion extends to a Breslow depth of 1.8 mm 
(Clark level IV). Margins are free of tumor (closest margin: deep, 0.3 cm).

---

Diagnosis

Specimen A, Skin, left forearm, excisional biopsy:

[DIAGNOSIS IN CAPITAL LETTERS]

Example Format:

MALIGNANT MELANOMA, SUPERFICIAL SPREADING TYPE

Pathologic features:
- Breslow thickness: 1.8 mm
- Clark level: IV
- Mitotic rate: 4/mm²
- Ulceration: Absent
- Margins: Negative for melanoma (closest margin deep, 0.3 cm)
- Lymphovascular invasion: Not identified
- Perineural invasion: Not identified
- Regression: Absent
- Tumor-infiltrating lymphocytes: Present, non-brisk
- Microsatellites: Absent

For Cancer Specimens - Synoptic Format (CAP Protocol):

SYNOPTIC REPORT FOR [CANCER TYPE]

Procedure: [Type of resection]
Tumor Site: [Specific location]
Tumor Size: [Greatest dimension in cm]
Histologic Type: [WHO classification]
Histologic Grade: [Grading system and result]
Depth of Invasion: [Measured in mm if applicable]
Lymphovascular Invasion: [Present / Not identified]
Perineural Invasion: [Present / Not identified]
Margins:
  - [Margin name]: [Negative/Positive, distance if negative]
  - [All margins listed]
Regional Lymph Nodes:
  - Number examined: [X]
  - Number with metastasis: [Y]
  - Extranodal extension: [Present/Absent]
Pathologic Stage (AJCC 8th edition): [pTNM]
Additional Findings: [Other relevant findings]

---

Ancillary Studies

Immunohistochemistry:

Example:

Molecular/Genetic Testing: [Results of molecular tests if performed]

• BRAF mutation: [Detected/Not detected]
• [Other relevant tests]

---

Comment

[Additional interpretive information, differential diagnosis, recommendations]

Example:

The morphologic and immunohistochemical findings are diagnostic of melanoma. The 
Breslow thickness of 1.8 mm places this tumor in the T2 category (AJCC 8th edition).
Sentinel lymph node biopsy is recommended for staging. BRAF mutation testing may be 
considered for treatment planning. Close clinical follow-up is recommended.

---

Signature

Pathologist: [Name, MD] [Board Certification] [License number]

Electronically signed: [Date and time]

Gross examination by: [Name, credentials] Microscopic examination by: [Name, MD]

---

Template Notes for Different Specimen Types

Breast Biopsy

Key Elements:

• Histologic type (invasive ductal, lobular, etc.)
• Nottingham grade (tubule formation, nuclear grade, mitotic count)
• Size of invasive component
• DCIS if present (grade, extent)
• ER/PR/HER2 status
• Margins for all components
• Lymph nodes if present

Colon Resection

Key Elements:

• Tumor site and size
• Histologic type and grade
• Depth of invasion (T stage)
• Lymph nodes (number positive/total examined)
• Margins (proximal, distal, radial/circumferential)
• Lymphovascular and perineural invasion
• Tumor deposits
• MSI/MMR status

Prostate Biopsy/Resection

Key Elements:

• Gleason score (pattern 1 + pattern 2 = total)
• Grade group (1-5)
• Percent involvement per core/specimen
• Extraprostatic extension (if radical prostatectomy)
• Seminal vesicle invasion
• Margins
• Perineural invasion

---

Frozen Section Report (if applicable)

Frozen Section Diagnosis:

Specimen: [Description] Clinical Question: [Reason for frozen] Frozen Section Diagnosis: [Diagnosis given intraoperatively] Time: [Time reported] Pathologist: [Name]

Note: Permanent sections to follow.

Final Diagnosis: [State if concordant or discordant with frozen]